

Clovis Oncology, Inc.
Form DEF 14A
April 26, 2017
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A INFORMATION

(Rule 14a-101)

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

Filed by the Registrant

Filed by a party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Under § 240.14a-12

Clovis Oncology, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

Table of Contents

(4) Date Filed:

Table of Contents

5500 Flatiron Parkway, Suite 100

Boulder, Colorado 80301

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON JUNE 8, 2017

Dear Stockholder:

You are cordially invited to attend the Annual Meeting of Stockholders of Clovis Oncology, Inc. The meeting will be held on Thursday, June 8, 2017 at 8:30 a.m. Mountain Time at the St. Julien Hotel, 900 Walnut Street, Boulder, Colorado 80302 for the following purposes:

1. To elect three Class III directors for a three year term;
2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017; and
3. To transact such other business as may properly come before the meeting or any adjournment thereof.

These items of business are more fully described in the proxy statement accompanying this notice.

The record date for the annual meeting is April 10, 2017. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof.

Your vote is very important. Please promptly submit your proxy as soon as possible (i) by accessing the Internet site or by calling the toll-free number described in the proxy materials; or (ii) if you receive a paper proxy card by mail, by completing and returning the proxy card mailed to you. Please note that all votes cast by telephone or on the Internet must be cast prior to 11:59 p.m., Eastern Time, on June 7, 2017. Submitting your proxy now will not limit your right to vote in person at the annual meeting if you desire to do so, as your proxy is revocable at your option.

By Order of the Board of Directors

Paul E. Gross

Secretary

Boulder, Colorado

April 26, 2017

Table of Contents

TABLE OF CONTENTS

	Page
<u>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 8, 2017</u>	
<u>TABLE OF CONTENTS</u>	
<u>PROXY STATEMENT</u>	1
<u>QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING</u>	1
<u>PROXY PROPOSALS</u>	
<u>Proposal 1: Election of Directors</u>	5
<u>Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm</u>	9
<u>INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</u>	10
<u>EXECUTIVE AND DIRECTOR COMPENSATION</u>	16
<u>COMPENSATION DISCUSSION AND ANALYSIS</u>	17
<u>SUMMARY COMPENSATION TABLE</u>	36
<u>DIRECTOR COMPENSATION</u>	44
<u>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</u>	46
<u>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</u>	50
<u>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</u>	51
<u>AVAILABLE INFORMATION</u>	52
<u>OTHER MATTERS</u>	53

Unless the context requires otherwise, references in this proxy statement to Clovis, the Company, we, us, and our to Clovis Oncology, Inc., together with its consolidated subsidiaries.

Table of Contents

CLOVIS ONCOLOGY, INC.

5500 FLATIRON PARKWAY, SUITE 100

BOULDER, COLORADO 80301

PROXY STATEMENT

2017 ANNUAL MEETING OF STOCKHOLDERS

JUNE 8, 2017

INFORMATION CONCERNING SOLICITATION AND VOTING

Our board of directors is soliciting proxies for our 2017 Annual Meeting of Stockholders, or the Annual Meeting, to be held on Thursday, June 8, 2017 at 8:30 a.m. Mountain Time at the St. Julien Hotel, 900 Walnut Street, Boulder, CO, 80302. If you need directions to the location of the Annual Meeting, please contact us at (303) 625-5000.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to Be Held on June 8, 2017:

Pursuant to the rules adopted by the Securities and Exchange Commission, or the SEC, we have elected to provide access to our proxy materials, including this Proxy Statement and our 2016 Annual Report, over the Internet. Accordingly, we are sending a Notice Regarding the Availability of Proxy Materials, or the Notice, to our stockholders of record entitled to vote at the Annual Meeting with instructions for accessing the proxy materials and voting over the Internet or by telephone. We intend to mail the Notice on or about April 26, 2017 to all stockholders entitled to vote at the Annual Meeting.

All stockholders entitled to vote at the Annual Meeting will have the ability to access the proxy materials on the website referred to in the Notice and to request to receive a printed set of the proxy materials. This makes the proxy distribution process more efficient and less costly and helps conserve natural resources. Instructions on how to access the proxy materials over the Internet or to request a printed copy of the proxy materials may be found in the Notice.

The Notice will also identify the date, the time and location of the Annual Meeting; the matters to be acted upon at the meeting and the Board of Directors' recommendation with regard to each matter; a toll-free telephone number, an e-mail address, and a website where stockholders can request to receive, free of charge, a paper or e-mail copy of the Proxy Statement, our Annual Report on Form 10-K for the year ended December 31, 2016, and a form of proxy relating to the Annual Meeting; information on how to access and vote the form of proxy; and information on how to obtain directions to attend the meeting and vote in person should stockholders choose to do so.

QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING

Why am I receiving these materials?

We are providing these proxy materials to you because the board of directors of Clovis Oncology, Inc. is soliciting your proxy to vote at the Annual Meeting to be held on June 8, 2017 at 8:30 a.m. Mountain Time, including at any adjournments or postponements of the meeting. We intend to begin sending the Notice and making our proxy materials available on or about April 26, 2017 to all stockholders of record entitled to vote at the Annual Meeting.

Edgar Filing: Clovis Oncology, Inc. - Form DEF 14A

You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may follow the instructions below to submit your proxy.

- 1 -

Table of Contents

Can I vote my shares by filling out and returning the Notice?

No. The Notice identifies the items to be voted on at the Annual Meeting, but you cannot vote by marking the Notice and returning it. The Notice provides instructions on how to vote over the Internet or by telephone, by requesting and returning a printed proxy card, or by submitting a ballot in person at the Annual Meeting.

How do I attend the Annual Meeting?

The meeting will be held on Thursday, June 8, 2017 at 8:30 a.m. Mountain Time at the St. Julien Hotel, 900 Walnut Street, Boulder, Colorado 80302.

What am I voting on?

There are two matters scheduled for a vote:

Proposal 1: Election of Directors. Election of Keith Flaherty, M.D., Ginger L. Graham and Edward J. McKinley as Class III directors to hold office until the 2020 annual meeting of stockholders; and

Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.

How many votes do I have?

On each matter to be voted upon, you have one vote for each share of common stock you own as of April 10, 2017.

How do I vote at the Annual Meeting?

With respect to the election of directors, you may either vote For all of the nominees to the board of directors or you may Withhold your vote for any nominee you specify. With respect to the ratification of the selection of our independent registered public accountants, you may vote For or Against or abstain from voting.

Only stockholders of record at the close of business on April 10, 2017 will be entitled to vote at the Annual Meeting. The procedures for voting are as follows:

Stockholder of Record: Shares Registered in Your Name

If on April 10, 2017 your shares were registered directly in your name with our transfer agent, Continental Stock Transfer & Trust Company, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person even if you have already voted by proxy.

To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive.

To vote using the printed proxy card that may be delivered to you, simply complete, sign and date the proxy card that may be delivered and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct.

To vote by Internet or telephone, follow the instructions on the website referred to in the Notice previously sent to you. Your vote must be received by 11:59 p.m. Eastern Time on June 7, 2017 to be counted.

- 2 -

Table of Contents

Beneficial Owner: Shares Registered in the Name of a Broker or Bank

If on April 10, 2017 your shares were registered, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in street name and you should have received a Notice from that organization. Simply follow the voting instructions in the Notice to ensure that your vote is counted. Alternatively, you may vote by telephone or over the internet as instructed by your broker or bank. To vote in person at the Annual Meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker or bank included with the proxy materials, or contact your broker or bank to request a proxy form.

What if I return a proxy card or otherwise vote but do not make specific choices?

If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, For the election of all three nominees for director and For the ratification of selection of the independent registered public accounting firm. If any other matter is properly presented at the meeting, your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.

What does it mean if I receive more than one Notice?

If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on the Notices to ensure that all of your shares are voted.

Can I change my vote after submitting my proxy?

Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:

You may submit another properly completed proxy card with a later date.

You may grant a subsequent proxy by telephone or over the Internet.

You may send a timely written notice that you are revoking your proxy to our Secretary at 5500 Flatiron Parkway, Suite 100, Boulder, CO 80301.

You may attend the Annual Meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy.

Your most current proxy card or telephone or Internet proxy is the one that is counted.

If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank.

What is the quorum requirement?

A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote are present at the meeting in person or represented by proxy. On the record date, there were 44,771,319 shares outstanding and entitled to vote. Thus, the holders of 22,385,660 shares must be present in person or represented by proxy at the meeting to have a quorum.

What vote is required to approve each proposal?

Proposal 1: Election of Directors. The three nominees who receive the most For votes (among votes properly cast in person or by proxy) will be elected. Only votes For will affect the outcome.

Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm. The ratification of the appointment of Ernst & Young LLP, our independent registered public accounting firm, must receive For votes from the holders of a majority of the shares of common stock present or represented by proxy and entitled to vote at the Annual Meeting.

Table of Contents

What is the effect of abstentions and broker non-votes?

Shares of common stock held by persons attending the Annual Meeting, but not voting, and shares represented by proxies that reflect abstentions as to a particular proposal will be counted as present for purposes of determining the presence of a quorum. Abstentions are treated as shares present in person or by proxy and entitled to vote, so abstaining has the same effect as a negative vote for purposes of the vote on the ratification of selection of independent registered public accounting firm. However, because the election of directors is determined by a plurality of votes cast, abstentions will not be counted in determining the outcome of that proposal.

Shares represented by proxies that reflect a broker non-vote will be counted for purposes of determining the presence of a quorum. A broker non-vote occurs when a nominee holding shares for a beneficial owner has not received instructions from the beneficial owner and does not have discretionary authority to vote the shares for certain non-routine matters. With regard to the election of directors, broker non-votes, if any, will not be counted as votes cast and will have no effect on the result of the vote. However, ratification of the selection of independent registered public accounting firm is considered a routine matter on which a broker or other nominee has discretionary authority to vote. As a result, broker non-votes will be counted for purposes of this proposal.

Who is paying for this proxy solicitation?

We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.

How can I find out the results of the voting at the Annual Meeting?

Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be disclosed in a Current Report on Form 8-K, or Form 8-K, that we expect to file with the Securities and Exchange Commission, or the SEC, within four business days after the Annual Meeting. If final voting results are not available to us in time to file with the SEC a Form 8-K within four business days after the meeting, we intend to file with the SEC a Form 8-K to disclose preliminary results and, within four business days after the final results are known to us, file with the SEC an additional Form 8-K to disclose the final results.

Table of Contents**PROPOSAL 1****ELECTION OF DIRECTORS**

Our board of directors is divided into three staggered classes of directors of the same or nearly the same number, designated Class I, Class II and Class III, with each class having a three year term. Vacancies on the board of directors may be filled by the affirmative vote of a majority of the remaining directors. A director elected by the board of directors to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director's successor is duly elected and qualified.

There are three directors in Class III whose term of office expires in 2017. Each of the nominees for election to Class III, Keith Flaherty, M.D., Ginger L. Graham and Edward J. McKinley, has been recommended by the nominating and corporate governance committee of the board of directors for election and nominated by the board of directors for election at the Annual Meeting and is currently a member of our board of directors. If re-elected at the Annual Meeting, each of these nominees would serve until our 2020 annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director's death, resignation or removal. If any nominee becomes unavailable for election as a result of an unexpected occurrence, shares that would have been voted for that nominee will instead be voted for the election of a substitute nominee proposed by us. Each person nominated for election has agreed to serve if elected. Our management has no reason to believe that any nominee will be unable to serve.

The following table sets forth the name, age and position of each of our nominees as of March 31, 2017:

Nominees for Election for a Three-Year Term Expiring at the 2017 Annual Meeting Class III

Name	Age	Position
Keith Flaherty, M.D.	46	Director
Ginger L. Graham	61	Director
Edward J. McKinley	65	Director

The following is biographical information as of March 31, 2017 for our nominees:

Dr. Keith Flaherty has served as a member of our board of directors since 2013. He is a Professor of Medicine at Harvard Medical School, Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital, and Director of the Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center. Dr. Flaherty is also the Deputy Chair for Biomarker Sciences and the Chair of the Developmental Therapeutics Committee in the Eastern Cooperative Oncology Group. Dr. Flaherty has served as Principal Investigator for numerous first-in-human clinical trials with novel, targeted therapies, including the first in-human trials of the first prospectively developed selective BRAF inhibitors for metastatic melanoma. He currently serves on the board of directors of Loxo Oncology, Inc. (NASDAQ: LOXO). Dr. Flaherty has a Bachelor of Science from Yale University and medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women's Hospital and completed a medical oncology fellowship at the University of Pennsylvania. We believe that Dr. Flaherty possesses specific attributes that qualify him to serve as a member of our board of directors, including his scientific background and experience as a clinician in the field of oncology, as well as his expertise reflected in his significant scientific and medical journal publications.

Ginger Graham has served as a member of our board of directors since 2013. She is the former President and CEO of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA focused on diabetes and obesity. Previously, Ms. Graham was Group Chairman, Office of the President for Guidant Corporation. She is the former President and CEO of Two Trees Consulting, where she coached first-time CEOs of public and

Table of Contents

private companies. She has been a senior lecturer at Harvard University and a faculty member in its Entrepreneurship Unit. Ms. Graham serves on the Boards of Directors for Elcelyx Therapeutics Inc., Genomic Health, Inc. (NASDAQ: GHDX), Surefire Medical and Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Ms. Graham has a Bachelor of Science, Agriculture with high honors from the University of Arkansas and a Master in Business Administration with distinction from Harvard Business School. We believe Ms. Graham possesses specific attributes that qualify her to serve as a member of our board of directors, including her years of business and leadership experience in the life sciences industry.

Edward J. McKinley has served as a member of our board of directors since our inception and serves as the chairman of our audit committee. Mr. McKinley spent 20 years serving in various roles at the private equity firm Warburg Pincus, including managing the firm's private equity activity in Europe and serving on the firm's Management Committee. Before joining Warburg Pincus, he was with the management consulting firm McKinsey & Company. Mr. McKinley also served on the board of Pharmion Corporation (acquired in 2008) and currently serves on the boards of several private companies, and as an advisor or investment committee head for several investment management firms. He also serves on the investment committee of several endowments, and on the boards or advisory boards of several non-profit organizations. He graduated Phi Beta Kappa with honors from Stanford University and holds a graduate management degree from Yale University. We believe that Mr. McKinley possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience in the venture capital industry, his years of business and leadership experience and his financial sophistication and expertise.

THE BOARD OF DIRECTORS RECOMMENDS**A VOTE FOR EACH NAMED NOMINEE.****Directors Continuing in Office Until the 2018 Annual Meeting Class I**

The following table sets forth the name, age and position of each of our directors in Class I as of March 31, 2017:

Name	Age	Position
Patrick J. Mahaffy	54	President and Chief Executive Officer; Director
M. James Barrett, Ph.D.	74	Chairman of the Board of Directors
Thorlef Spickschen	76	Director

The following is biographical information as of March 31, 2017 for our directors in Class I:

Patrick J. Mahaffy is one of our co-founders and has served as our President and Chief Executive Officer and a member of our board of directors since our inception. Previously, Mr. Mahaffy served as President and Chief Executive Officer and as a member of the board of directors at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. From 1992 through 1998, Mr. Mahaffy was President and Chief Executive Officer of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals, Inc., a biopharmaceutical company. Prior to that, Mr. Mahaffy was a Vice President at the private equity firm E.M. Warburg Pincus and Co. Mr. Mahaffy also serves on the boards of directors of Flexion Therapeutics, Inc. (NASDAQ: FLXN) and Orexigen Therapeutics, Inc. (NASDAQ: OREX). He is also a trustee of Lewis and Clark College. Mr. Mahaffy has a B.A. in international affairs from Lewis and Clark College and a M.A. in international affairs from Columbia University. We believe that Mr. Mahaffy possesses specific attributes that qualify him to serve as a member of our board of directors, including his understanding of our business and strategy in his role as our CEO, his experience in the venture capital industry, his historical knowledge, his operational and management expertise and his years of leadership experience.

Dr. M. James Barrett has served as a member of our board of directors since our inception and serves as the chairman of our board of directors, and the chairman of our nominating and corporate governance committee. Since September 2001, he has served as a general partner of New Enterprise Associates Inc., a venture capital

firm focusing on the healthcare, information technology and energy technology industries. From 1997 to 2001, Dr. Barrett served as Chairman and Chief Executive Officer of Sensors for Medicine and Science, which he

Table of Contents

founded in 1997. Dr. Barrett serves on the boards of several pharmaceutical and biotechnology companies, including Galera Therapeutics, Inc., GlycoMimetics, Inc. (NASDAQ: GLYC), PhaseBio Pharmaceuticals, Inc., Placon Therapeutics, Inc., Proteostasis Therapeutics, Inc. (NASDAQ: PTI), Psyadon Pharmaceuticals, Inc. (f/k/a Ruxton Pharmaceuticals, Inc.), Roka Bioscience, Inc. (NASDAQ: ROKA), Senseonics Holdings (NYSE: SENS) and Tarveda Therapeutics, Inc. (f/k/a Blend Biosciences, Inc.), as well as continuing to serve as Chairman of Sensors for Medicine and Science. Dr. Barrett previously served on the boards of, among others, Amicus Therapeutics, Inc. (NASDAQ: FOLD), Inhibitex, Inc. (NASDAQ: INHX) (acquired by Bristol-Myers Squibb (NASDAQ: BMY)), Loxo Oncology, Inc. (NASDAQ: LOXO), Pharmion Corporation (acquired in 2008), Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), Targacept, Inc. (NASDAQ: TRGT), YM Biosciences, Inc. (AMEX: YMI) and Zosano Pharma Corporation (NASDAQ: ZSAN). Dr. Barrett received a Ph.D. in biochemistry from the University of Tennessee, his M.B.A. from the University of Santa Clara, and a B.S. in chemistry from Boston College. We believe that Dr. Barrett possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience in the venture capital industry and his years of business and leadership experience.

Dr. Thorlef Spickschen has served as a member of our board of directors since our inception. From 2005 to 2012, Dr. Spickschen was chairman of Biotest AG, a publicly-traded biotechnology company in Germany. From 1994 to 2001, he was chairman and chief executive officer of BASF Pharma/Knoll AG. From 1984 to 1994, Dr. Spickschen worked with Boehringer Mannheim GmbH, where he was responsible for sales and marketing and has been chairman of its Executive Board since 1990. From 1976 to 1984, Dr. Spickschen was Managing Director, Germany and Central Europe for Eli Lilly & Co. Dr. Spickschen is currently chairman of the advisory board of Heidelberg Innovation, a venture capital firm in life sciences/healthcare, and chairman of Verein Deutsche Nierenstiftung, sponsoring the German kidney foundation. Dr. Spickschen also served on the board of Pharmion Corporation from December 2001 through the company's acquisition in 2008. Dr. Spickschen received a Doctorate in business management from the University of Cologne. We believe that Dr. Spickschen possesses specific attributes that qualify him to serve as a member of our board of directors, including his business and leadership experience in the biomedical industry.

Directors Continuing in Office Until the 2019 Annual Meeting Class II

The following table sets forth the name, age and position of each of our directors in Class II as of March 31, 2017:

Name	Age	Position
Brian G. Atwood	64	Director
James C. Blair, Ph.D.	77	Director
Paul H. Klingenstein	61	Director

The following is biographical information as of March 31, 2017 for our directors in Class II:

Brian G. Atwood has served as a member of our board of directors since our inception. He is President and CEO as well as a co-founder of Cell Design Labs, Inc., a biotechnology company focused on developing human cell engineering technology for the treatment of multiple diseases, including cancer. In 1999, he co-founded and currently serves as a Managing Director for Versant Ventures, a healthcare-focused venture capital firm. Prior to founding Versant Ventures, Mr. Atwood served as a general partner of Brentwood Associates, a venture capital firm. Mr. Atwood also serves on the boards of several pharmaceutical and biotechnology companies, including Atreca, Inc., Immune Design Corp. (NASDAQ: IMDZ), OpGen, Inc. (NASDAQ: OPGN), PhaseRx, Inc., and Veracyte, Inc. (NASDAQ: VCYT). Mr. Atwood also served on the boards of Five Prime Therapeutics (NASDAQ: FPRX), Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) acquired in 2014, Helicos Biosciences (NASDAQ: HLCS), Pharmion Corporation (acquired in 2008) and Trius Therapeutics, Inc. (NASDAQ: TSRX) acquired in 2013. Mr. Atwood holds

a B.S. in biological sciences from the University of California, Irvine, a M.S. in ecology from the University of California, Davis, and an M.B.A. from Harvard University. We believe that Mr. Atwood possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience in the venture capital industry, his years of business and leadership experience and his financial sophistication and expertise.

Table of Contents

James C. Blair, Ph.D. has served as a member of our board of directors since our inception and serves as the chairman of our compensation committee. Since 1985, he has served as a general partner of Domain Associates, L.L.C., a venture capital management company focused on life sciences. Dr. Blair currently serves on the boards of Applied Proteomics, Inc., Astute Medical, Inc., aTyr Pharma, Inc., ChromaCode, Inc., IntegenX, Inc. and OcuNexus Therapeutics, Inc. He has previously served on the boards of over 40 life science ventures including Amgen Inc. (NASDAQ: AMGN), Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Applied Biosystems Inc., Aurora Biosciences Corp., Dura Pharmaceuticals, Inc., Nuvasive, Inc. (NASDAQ: NUVA), Pharmion Corporation (acquired in 2008), Volcano Corporation (NASDAQ: VOLC) and Zogenix, Inc. (NASDAQ: ZGNX). Dr. Blair currently serves on the board of directors of the Prostate Cancer Foundation and the Sanford-Burnham Medical Research Institute. He is also on the advisory boards of the Department of Molecular Biology at Princeton University, the USC Stevens Institute for Innovation, and the Division of Chemistry and Chemical Engineering at the California Institute of Technology. He received a B.S.E. from Princeton University and M.S.E. and Ph.D. degrees from the University of Pennsylvania, all in electrical engineering. We believe that Dr. Blair possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience in the life science industry and his years of business and leadership experience.

Paul H. Klingenstein has served as a member of our board of directors since our inception. He is the Managing Partner of Aberdare Ventures, a healthcare-focused venture capital firm he formed in 1999. Prior to founding Aberdare, Mr. Klingenstein worked in venture capital with Warburg Pincus and Accel Partners, and was an advisor to the Rockefeller Foundation. Mr. Klingenstein currently serves on the boards of several private companies. Mr. Klingenstein has previously served on the boards of Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), Aviron Inc., Conatus Pharmaceuticals Inc. (NASDAQ: CNAT), EnteroMedics Inc. (NASDAQ: ETRM), Glycomed Inc., Isis Pharmaceuticals, Inc., now Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), Pharmion Corporation (acquired in 2008), Viagene Inc., and Xomed Surgical Products Inc. He is currently a board member of the MacArthur Foundation and the London School of Hygiene and Tropical Medicine. He has also served on the boards of various educational and non-profit institutions. Mr. Klingenstein received an A.B. in anthropology from Harvard University and an M.B.A. from Stanford University. We believe that Mr. Klingenstein possesses specific attributes that qualify him to serve as a member of our board of directors, including his experience in the venture capital industry and his years of business and leadership experience.

Table of Contents**PROPOSAL 2****RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

The audit committee of our board of directors has selected Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2017 and has further directed that management submit the selection of independent registered public accounting firm for ratification by the stockholders at the Annual Meeting. Ernst & Young LLP has audited our financial statements since 2009. Representatives of Ernst & Young LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be available to respond to appropriate questions.

Neither our amended and restated bylaws nor our other governing documents or law require stockholder ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm. However, the audit committee is submitting the selection of Ernst & Young LLP to the stockholders for ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the audit committee will reconsider whether or not to retain that firm. Even if the selection is ratified, the audit committee in its discretion may direct the appointment of different independent auditors at any time during the year if they determine that such a change would be in our best interests or those of our stockholders.

The affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote at the Annual Meeting will be required to ratify the selection of Ernst & Young LLP. Abstentions will be counted toward the tabulation of votes on this proposal presented to the stockholders and will have the same effect as negative votes.

Principal Accountant Fees and Services

The following table represents aggregate fees billed to us for the years ended December 31, 2016 and December 31, 2015, by Ernst & Young LLP, our principal accountant.

	Year Ended December 31,	
	2016	2015
Audit Fees ⁽¹⁾	\$ 548,779	\$ 519,453
Audit Related Fees ⁽²⁾	86,000	55,300
Tax Fees ⁽³⁾	101,464	97,808
	\$ 736,243	\$ 672,561

- (1) Audit fees include fees associated with the annual audit of our financial statements, the reviews of our interim financial statements, and all services that are normally provided by the accounting firm in connection with statutory and regulatory filings or engagements.
- (2) Audit related fees include fees associated with professional services related to our public offerings of securities.
- (3) Tax fees include fees associated with tax compliance, tax advice and tax planning.
- All fees described above for the year ended December 31, 2016 were approved by our audit committee.

Pre-Approval Policies and Procedures

The audit committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by our independent registered public accounting firm, Ernst & Young LLP. Pre-approval may also be given as part of the audit committee's approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis before the independent auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the audit committee's members, but the decision must be reported to the full audit committee at its next scheduled meeting.

THE BOARD OF DIRECTORS RECOMMENDS

A VOTE FOR THIS PROPOSAL 2.

Table of Contents

**INFORMATION REGARDING THE BOARD OF DIRECTORS
AND CORPORATE GOVERNANCE**

Board Independence

Rule 5605 of the NASDAQ Marketplace Rules requires a majority of a listed company's board of directors to be comprised of independent directors within one year of listing. In addition, the NASDAQ Marketplace Rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating and governance committees be independent and that audit committee members also satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act. Under Rule 5605(a)(2), a director will only qualify as an independent director if, in the opinion of our board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee: (1) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries.

Our board of directors has undertaken a review of the composition of our board of directors and its committees and the independence of each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that none of Drs. Barrett, Blair, Flaherty, and Spickschen, Ms. Graham, or Messrs. Atwood, Klingenstein and McKinley, representing eight of our nine directors, has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is independent as that term is defined under Rule 5605(a)(2) of the NASDAQ Marketplace Rules.

Our board of directors also determined that Messrs. Atwood, Klingenstein, and McKinley, who comprise our audit committee, Drs. Barrett, Blair, Spickschen, and Ms. Graham, who comprise our compensation committee, and Drs. Barrett, Blair, Flaherty, and Mr. Atwood, who comprise our nominating and corporate governance committee, satisfy the independence standards for such committees established by the SEC and the NASDAQ Marketplace Rules, as applicable. In making such determination, our board of directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee director.

Board Leadership Structure

Our board of directors has an independent Chairman, M. James Barrett. Our board of directors recognizes that it is important to determine an optimal board leadership structure to ensure the independent oversight of management as we continue to grow. We separate the roles of Chief Executive Officer and Chairman of the board of directors in recognition of the differences between the two roles. The Chief Executive Officer is responsible for setting our strategic direction, day-to-day leadership and performance, while the Chairman of the board of directors provides guidance to the Chief Executive Officer and presides over meetings of the full board of directors. We believe that this separation of responsibilities provides a balanced approach to management of our board of directors and oversight of us. However, no single leadership model is right for all companies and at all times. The board of directors recognizes that depending on the circumstances, other leadership models, such as combining the role of Chairman with the role of Chief Executive Officer, might be appropriate. Accordingly, the board of directors may periodically review its leadership structure.

Board's Role in Risk Oversight

Our audit committee is primarily responsible for overseeing our risk management processes on behalf of the full board of directors. The audit committee receives reports from management at least quarterly regarding our

Table of Contents

assessment of risks. In addition, the audit committee reports regularly to the full board of directors, which also considers our risk profile. The audit committee and the full board of directors focus on the most significant risks we face and our general risk management strategies. While our board of directors oversees our risk management, company management is responsible for day-to-day risk management processes. Our board of directors expects company management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and processes for day-to-day activities and to effectively implement risk management strategies adopted by the audit committee and the board of directors. We believe this division of responsibilities is the most effective approach for addressing the risks we face and that our board leadership structure, which also emphasizes the independence of the board in its oversight of our business and affairs, supports this approach.

Board Meetings

During the fiscal year 2016, our board of directors met 10 times, including telephonic meetings. In that year, each director attended at least 75% of the aggregate of the meetings held by the board of directors, and each director who is a member of a committee attended at least 75% of the meetings the committees of our board of directors held on which the director served. All of our directors attended our annual meeting of stockholders in 2016. It is our policy to encourage directors and nominees for director to attend the Annual Meeting.

Information Regarding Board Committees

Our board of directors has established three standing committees: an audit committee, a compensation committee, and a nominating and corporate governance committee. The following table provides membership and meeting information for 2016 for each of the board of directors committees:

Name	Audit	Compensation	Nominating and Corporate Governance
<i>Employee Director:</i>			
Patrick J. Mahaffy			
<i>Non-Employee Directors:</i>			
Brian G. Atwood	X		X
M. James Barrett		X	X*
James C. Blair		X*	X
Keith Flaherty			X
Ginger L. Graham		X	
Paul H. Klingenstein	X		
Edward J. McKinley	X*		
Thorlef Spickschen		X	
Total meetings in 2016:	4	6	3

* Committee Chair

Below is a description of each committee of the board of directors.

Audit Committee

The members of the audit committee are Messrs. Atwood, Klingenstein, and McKinley, each of whom qualifies as an independent director under the corporate governance standards of the NASDAQ Stock Market and the independence requirements of Rule 10A-3 of the Exchange Act. Our board of directors has determined that Mr. McKinley qualifies as an audit committee financial expert as such term is defined in Item 407(d)(5) of Regulation S-K. Mr. McKinley serves as chairman of this committee. During the fiscal year 2016, our audit committee met four times, including telephonic meetings.

Table of Contents

Our audit committee oversees a broad range of issues surrounding our accounting and financial reporting processes and audits of our financial statements, and assists our board of directors by: (1) overseeing and monitoring the quality and integrity of our financial statements, our compliance with legal and regulatory requirements and our internal accounting procedures and systems of internal controls (2) assuming direct responsibility for the appointment, compensation, retention and oversight of work of any independent registered public accounting firm engaged for the purpose of performing any audit, review or attestation services, for overseeing and monitoring our independent registered public accounting firm's qualifications and independence, and for dealing directly with any such accounting firm, including resolving disagreements between management and our independent auditor; (3) providing a medium for consideration of matters relating to any audit issues; and (4) preparing the audit committee report required to be included in our filings under the rules and regulations of the SEC. The written charter for the audit committee is available on our website at <http://ir.clovisoncology.com> under Corporate Governance.

Table of Contents

REPORT OF THE AUDIT COMMITTEE

Our audit committee has reviewed our audited financial statements for the fiscal year ended December 31, 2016 and discussed them with our management and our independent registered public accounting firm, Ernst & Young LLP.

Our audit committee has also received from, and discussed with, Ernst & Young LLP various communications that Ernst & Young LLP is required to provide to our audit committee, including the matters required to be discussed by Auditing Standard No. 16, *Communications with Audit Committees*, as adopted by the Public Company Accounting Oversight Board.

In addition, our audit committee has received the written disclosures and the letter from Ernst & Young LLP required by applicable requirements of the Public Company Accounting Oversight Board regarding Ernst & Young LLP's communications with our audit committee concerning independence, and has discussed with Ernst & Young LLP their independence.

Based on the review and discussions referred to above, our audit committee has recommended to the board of directors that the audited financial statements be included in the annual report on Form 10-K for the year ended December 31, 2016, filed by us with the SEC.

Respectfully submitted,

The Audit Committee of the Board of Directors

Brian G. Atwood

Paul H. Klingenstein

Edward J. McKinley

The material in this report is not soliciting material, shall not be deemed filed with the SEC and shall not to be incorporated by reference in any filing of Clovis Oncology, Inc. under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

Compensation Committee

The members of the compensation committee are Drs. Barrett, Blair, and Spickschen and Ms. Graham, each of whom qualifies as an independent director under the corporate governance standards of the NASDAQ Stock Market. Each member of our compensation committee is a non-employee director, as defined in Rule 16b-3 promulgated under the Exchange Act and is an outside director, as defined pursuant to Section 162(m) of the Code. Dr. Blair serves as chairman of this committee. During fiscal year 2016, our compensation committee met six times, including telephonic meetings.

The compensation committee assists our board of directors in discharging its responsibilities relating to (1) setting our compensation program and compensation and benefits of all of our executive officers and directors; (2) providing oversight for our incentive and equity-based compensation plans; (3) establishing and reviewing general policies relating to compensation and benefits of our employees; and (4) preparing the compensation committee report required to be included in our filings under the rules and regulations of the SEC. The compensation committee may

form and delegate authority to subcommittees consisting of one or more members when appropriate, except that it shall not delegate to a subcommittee any power or authority required by any law, regulation or listing standard to be exercised by the compensation committee as a whole. The compensation committee will review and evaluate, at least annually, the performance of the compensation committee and its members, including compliance of the compensation committee with its charter. The written charter for the compensation committee is available on our website at <http://ir.clovisoncology.com> under Corporate Governance.

Table of Contents

Compensation Committee Interlocks and Insider Participation

No member of our compensation committee has ever been an executive officer or employee of ours. For a description of certain transactions between us and certain members of our compensation committee and their affiliated entities, see Certain Relationships and Related Party Transactions below. None of our officers currently serves, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more officers serving as a member of our board of directors or compensation committee.

Nominating and Corporate Governance Committee

The members of the nominating and corporate governance committee are Drs. Barrett, Blair, and Flaherty and Mr. Atwood, each of whom qualifies as an independent director under the corporate governance standards of the NASDAQ Stock Market. Dr. Barrett serves as chairman of this committee. During fiscal year 2016, our nominating and corporate governance committee met three times.

The nominating and corporate governance committee assists our board of directors in discharging its responsibilities relating to (1) developing and recommending criteria for selecting new directors, and identifying, screening and recommending nominees for election as directors; (2) screening and recommending to the board of directors individuals qualified to become executive officers; (3) evaluating our board of directors and its dealings with management; (4) developing, reviewing and recommending corporate governance guidelines and a code of business ethics; (5) generally advising our board of directors on other corporate governance and related matters; and (6) overseeing non-financial compliance. The written charter for the nominating and corporate governance committee is available on our website at <http://ir.clovisoncology.com> under Corporate Governance.

Director Nomination Process

Our nominating and corporate governance committee is responsible for identifying, considering and recommending director candidates to fill new positions or vacancies on our board of directors, including candidates proposed by our stockholders, except where the right to nominate a director legally belongs to a third party. Our board of directors is responsible for recommending a slate of directors for election by our stockholders.

In identifying individual candidates, our nominating and corporate governance committee considers current members of our board of directors, as well as candidates referred or recommended to it by directors, members of management, stockholders and others. In evaluating the suitability of individual candidates (both new candidates and current directors), our nominating and corporate governance committee, in recommending candidates for election, and our board of directors, in approving (and, in the case of vacancies, appointing) such candidates, takes into account many factors, including personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly held company; commercialization experience in pharmaceutical companies; strong finance experience; experience relevant to us; experience as a board member of another publicly held company; diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; diversity of background and perspective, including with respect to age, gender, race, place of residence and specialized experience; and practical and mature business judgment, including the ability to make independent analytical inquiries. The board of directors evaluates each individual in the context of the board of directors as a whole, with the objective of assembling a group that can best perpetuate the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas. In determining whether to recommend a director for re-election, the nominating and corporate governance committee may also consider the director's past attendance at meetings and participation in and contributions to the activities of the board of directors. The nominating and corporate governance committee is

responsible for reviewing with the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole and its individual members.

Table of Contents

We have not received director candidate recommendations from our stockholders. We do not have a formal policy regarding consideration of such recommendations because any recommendations received from stockholders will be evaluated in the same manner that potential nominees suggested by board members, management or other parties are evaluated. We do not intend to treat stockholder recommendations in any manner different from other recommendations.

Stockholders wishing to make director candidate recommendations should address such recommendations to our corporate secretary, Paul E. Gross, at Clovis Oncology, Inc., 5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301, in accordance with the procedures detailed under the heading **Stockholder Proposals to be Presented at Next Annual Meeting** below.

Stockholder Communications with the Board of Directors

Stockholders seeking to communicate with our board of directors should submit their written comments to our corporate secretary, Paul E. Gross, at Clovis Oncology, Inc., 5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301. The corporate secretary will forward such communications to each member of our board of directors; provided that, if in the opinion of our corporate secretary it would be inappropriate to send a particular stockholder communication to a specific director, such communication will only be sent to the remaining directors (subject to the remaining directors concurring with such opinion).

Code of Business Ethics

We have adopted the Clovis Oncology, Inc. Code of Business Ethics that is reviewed and published annually and contains the ethical principles by which our chief executive officer and chief financial officer, among others, are expected to conduct themselves when carrying out their duties and responsibilities. We intend to satisfy the disclosure requirements under Item 5.05 of Form 8-K regarding amendments to, or waivers from, a provision of our Code of Business Ethics by posting such information on our website at www.clovisoncology.com. Our Code of Business Ethics is available on our website at <http://ir.clovisoncology.com> under **Corporate Governance**.

Table of Contents**EXECUTIVE AND DIRECTOR COMPENSATION****Executive Officers**

The following table sets forth the name, age and position of each of our executive officers as of March 31, 2017:

Name	Age	Position
Patrick J. Mahaffy	54	President and Chief Executive Officer; Director
Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM	49	Executive Vice President of Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
Gillian C. Ivers-Read	63	Executive Vice President of Technical Operations and Chief Regulatory Officer
C. Dale Hooks	50	Senior Vice President and Chief Commercial Officer
Daniel W. Muehl	54	Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer

The following is biographical information as of March 31, 2017 for our executive officers other than Mr. Mahaffy, whose biographical information appears above in Proposal 1, Election of Directors.

Dr. Lindsey Rolfe has served as our Executive Vice President of Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer since August 2015. Dr. Rolfe joined Clovis in April 2010 and served as Senior Vice President of Clinical Development until her promotion. Dr. Rolfe has 19 years of drug development experience and previously served in senior oncology development roles at Celgene Corporation, Pharmion Corporation (acquired in 2008), Cambridge Antibody Technology, UCB Inc. and Celltech Group plc. Dr. Rolfe qualified in medicine at the University of Edinburgh. She undertook post graduate medical training in London, UK and obtained her post-graduate internal medicine qualification as a Member of the Royal College of Physicians (MRCP). She has specialist accreditation in Pharmaceutical Medicine from the UK General Medical Council and is a Fellow of the Faculty of Pharmaceutical Medicine.

Gillian C. Ivers-Read is one of our co-founders and has served as our Executive Vice President of Technical Operations and Chief Regulatory Officer since our inception. Previously, Ms. Ivers-Read served as Executive Vice President, Development Operations at Pharmion Corporation (acquired in 2008), beginning in 2002. From 1996 to 2001, Ms. Ivers-Read held various regulatory positions with Hoechst Marion Roussel and its successor, Aventis Pharmaceuticals, Inc., where she most recently held the position of Vice President, Global Regulatory Affairs. From 1994 to 1996, Ms. Ivers-Read was Vice President, Development and Regulatory Affairs for Argus Pharmaceuticals, and from 1984 to 1994, she served as a regulatory affairs director for Marion Merrell Dow. Ms. Ivers-Read received a B.Sc. in pharmacology from University College London.

C. Dale Hooks has served as our Senior Vice President and Chief Commercial Officer since January 2016. Mr. Hooks joined Clovis in August 2014 and served as Vice President of Sales until his promotion. Prior to joining Clovis, from 2004 to 2014, Mr. Hooks held many marketing and sales leadership positions at Genentech, Inc., including Franchise Head, Sales and Marketing of the skin cancer franchise. During his tenure at Genentech, he was responsible for the commercialization and launch of several key oncology brands across a variety of solid tumor categories, including lung, breast, colorectal, pancreatic and gastric cancers. Prior to Genentech, Mr. Hooks served in a number of sales and marketing leadership roles at GSK, Novartis and Galderma. Mr. Hooks has a B.S. degree in Marketing and Finance from Stephen F. Austin University and an M.B.A. from the University of North Carolina at Chapel Hill.

Daniel W. Muehl was appointed our Principal Accounting Officer and Principal Financial Officer in March 2016 and has served as our Senior Vice President of Finance since September 2016 and, prior to that, as our Vice President of Finance since 2015. Previously, Mr. Muehl was the Chief Financial Officer of biotechnology company Somalogic, Inc. from 2014 to 2015 and prior to that the Chief Financial Officer of bio-industrial company OPX Biotechnologies, Inc. from 2010 to 2014. He earned a Bachelor of Science degree in accounting from the University of Massachusetts Amherst and received his Certified Public Accountant certificate in 1990.

Table of Contents

COMPENSATION DISCUSSION AND ANALYSIS

Executive Summary

We are a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. We generally target our development programs for the treatment of specific subsets of cancer populations and seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients that are most likely to benefit from their use. We believe in rewarding our employees for helping us achieve our goals and delivering exceptional performance. Consistent with this general philosophy, we have designed our executive compensation program to tie a significant portion of an executive's overall compensation to the achievement of our corporate goals and increases in stockholder value.

To help ensure our executives' pay is aligned with our overall business strategy, our executive compensation program is driven by a core set of objectives which are supported by our overall compensation philosophy:

Objectives	Philosophy
<p>Our executive compensation program is designed to:</p> <p>Attract, motivate and retain talented executives who have the skills to drive our future growth and development.</p> <p>Align executive and stockholder interests and our long-term interests through equity ownership requirements and grants of equity based awards.</p> <p>Motivate the achievement of key strategic financial and operational goals that maximize rational growth. We have developed our executive compensation program to align with current governance and best practices while being able to achieve our stated objectives and philosophy and support our ambitious business goals:</p>	<p>Our executive compensation philosophy is built on the following principles:</p> <p>Position compensation competitively in the marketplace.</p> <p>Motivate our executives to achieve the greatest possible returns for our stockholders.</p> <p>Reward results for achieving strong company-wide and individual performance (pay-for-performance).</p>

What We Do

What We Don't Do

Maintain an industry-specific peer group for benchmarking pay × Allow hedging or pledging of equity

× Re-price stock options

Target pay based on market norms

× Provide excessive perquisites

Deliver executive compensation primarily through performance-based pay

× Provide supplemental executive retirement plans

Award bonuses commensurate with performance

Set challenging short- and long-term incentive award goals

Provide strong oversight that ensures adherence to incentive grant regulations and limits

Maintain a clawback policy for equity and incentive compensation

Require minimum levels of stock ownership by executives and directors

Require holding period for shares realized by executives from stock option exercises or equity award settlement

Offer market-competitive benefits for executives that are consistent with the rest of our employees

Consult with an independent advisor on compensation levels and practices

Table of Contents

In addition to our financial performance, we consider stockholder input and market pay practices when determining the appropriate compensation levels for our executives. The following individuals were our named executive officers of Clovis Oncology for 2016:

Named Executive Officer	Role	Tenure
Mr. Patrick J. Mahaffy	President and Chief Executive Officer; Director	Co-Founder ¹
Mr. Daniel W. Muehl	Senior Vice President, Finance	2 years ²
Ms. Gillian C. Ivers-Read	Executive Vice President, Technical Operations and Chief Regulatory Officer	Co-Founder ¹
Dr. Lindsey Rolfe	Executive Vice President of Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer	7 years
Mr. C. Dale Hooks	Senior Vice President and Chief Commercial Officer	3 years ³
Mr. Erle T. Mast	Former Executive Vice President and Chief Financial Officer	Co-Founder ⁴

¹ Clovis Oncology was founded in 2009.

² Prior to his promotion in August 2016, Mr. Muehl was Vice President of Finance. Since the departure of Mr. Mast in March 2016, Mr. Muehl has served as our Principal Financial Officer and Principal Accounting Officer.

³ Prior to his promotion in March 2016, Mr. Hooks was Vice President of Sales.

⁴ Mr. Mast retired from Clovis Oncology in March 2016, at which time he ceased to serve as our Principal Financial Officer and Principal Accounting Officer.

2016 Performance

We continued our focus on acquiring, developing and commercializing anti-cancer agents in 2016. In December, the U.S. Food and Drug Administration (FDA) approved Rubraca™ (rucaparib) tablets as monotherapy for the treatment of patients with advanced ovarian cancer – an important achievement for the company, which then supported our ability to raise net proceeds of \$221.2 million in a financing in early January 2017. We also submitted a Marketing Authorization Application (MAA) for rucaparib to the European Medicines Agency and entered into a long-term manufacturing and supply agreement with Lonza, the manufacturer of the active pharmaceutical ingredient (API) for rucaparib, in support of rucaparib's anticipated U.S. commercial launch.

Following notification from the FDA that we could anticipate receiving a Complete Response Letter (CRL) for the rociletinib NDA on or before the Prescription Drug User Fee Act (PDUFA) meeting date of June 28, 2016, and in anticipation of receiving the CRL, we terminated enrollment in all ongoing sponsored clinical studies of rociletinib and withdrew our MAA for rociletinib previously filed with European regulatory authorities. In connection with such termination and withdrawal, we eliminated contractor positions and delayed or eliminated planned new positions, resulting in the reduction of staff and contractor positions. However, we maintained our U.S. sales force in preparation for the potential U.S. launch of rucaparib as we determined that eliminating the U.S. sales force and replacing it with a contract organization to support the potential U.S. launch of rucaparib in Q4 2016 or Q1 2017 would not result in cost savings. Successful retention of the U.S. sales force enabled us to rapidly launch Rubraca following FDA approval in December.

Additionally, we completed target enrollment in the ARIEL3 pivotal maintenance study for Rubraca in the second quarter of 2016. If data from the ARIEL3 study is positive, we intend to follow up with a supplemental NDA for second-line maintenance therapy in women with ovarian cancer who have responded to platinum-based therapy.

Total Shareholder Return (TSR)

Our five-year annualized total shareholder return of 25.8% demonstrates that we are creating long-term value for our stockholders.

- 18 -

Table of Contents

Throughout the year, we worked toward the following corporate goals:

FDA approval of the commercial distribution, sale or marketing of rucaparib and U.S. commercial launch promptly following such approval;

Realizing cost savings while successfully retaining the U.S. sales force to enable us to rapidly launch Rubraca following FDA approval;

Submitting an MAA for rucaparib to the European Medicines Agency;

Entering into a long-term manufacturing and supply agreement with Lonza in support of rucaparib's anticipated U.S. commercial launch; and

Completing target enrollment in the ARIEL3 pivotal maintenance study for Rubraca.

Based on our operational and financial performance in 2016, the target cash bonuses for our named executive officers paid out above target levels for the year. See page 20 for details on annual incentive award decisions. Overall, executive compensation for 2016 reflects our compensation objectives and our operating performance, demonstrating a long-standing commitment to pay our executives based upon the performance they deliver.

Overview of 2016 Compensation Decisions and Actions

The table below summarizes the decisions that the compensation committee made for 2016 relative to our named executive officers' compensation, as well as updates to the compensation programs for 2017.

Factors Guiding Our Decisions

The following factors guided the compensation decisions for 2016:

Executive compensation program objectives and philosophy (see page 17);

Degree of achievement of key strategic financial and operational goals for 2015 (for salary and long-term incentive grant decisions made in early 2016) and for 2016 (for annual incentive plan payments in early 2017 and long-term incentive grant decisions made in late 2016). See page 32 for our 2016 goals and performance;

Recommendations of our President and Chief Executive Officer (CEO) (other than with respect to his own compensation) (see page 24);

Advice of an independent outside compensation consultant (see page 24);

Market pay practices as benchmarked by our independent consultant, including examining trends; and

Current and historical compensation.

**Key 2016
Compensation
Decisions**

Base Salary

In order to provide our named executive officers with base salaries that are competitive with our publicly-traded peer companies, base salaries were increased effective March 1, 2016. Ms. Ivers-Read received a base salary increase of 3%. Also, effective March 1, 2016, Dr. Rolfe received an increase of 11.5% to align her salary with the 50th percentile of the company's peer group. In addition, Mr. Hooks received base salary increases totaling 10.8% in connection with his promotion to Chief Commercial Officer. Mr. Muehl received an increase of 11.9% in connection with his promotion to Senior Vice President, Finance. Mr. Mahaffy did not receive a base salary increase for 2016, nor did Mr. Mast as his retirement had previously been announced.

In April 2016, based on his recommendation to the compensation committee and the committee's review of the company's operating performance, Mr. Mahaffy voluntarily waived his right to receive any base salary in excess of \$1 (plus the cost of any employee-paid premiums for health and welfare benefits) until the FDA approved the commercial distribution, sale or marketing of rucaparib. Upon the FDA's approval of rucaparib in December 2016, Mr. Mahaffy's base salary was reinstated to its normal rate.

See page 22 for details.

Table of Contents

Annual Performance Bonus

The compensation committee awarded above-target bonus payouts at 150% of target for Messrs. Mahaffy, Hooks and Muehl, Ms. Ivers-Read, and Dr. Rolfe in March 2017 based on 2016 year-end corporate performance, as well as their own individual performance. Mr. Mast did not receive an award as he retired from the company prior to bonus payout.

See page 32 for details on performance bonuses awarded for 2016 performance in early 2017.

Equity Compensation

Given our uncertainty regarding the FDA's approval of rucaparib, we delayed our annual spring equity grants to executive officers until August 2016. As a result, Mr. Mahaffy received no equity awards during 2016, and Dr. Rolfe and Ms. Ivers-Read did not receive equity awards during 2016 prior to the grants noted below made in connection with the approval by the FDA of the commercial distribution and sale of Rubraca. In addition, we made special one-time grants to Mr. Muehl and Mr. Hooks in connection with each of their promotions.

In February 2016, Mr. Hooks received 10,000 stock options in connection with his promotion to Chief Commercial Officer.

In March 2016, and prior to becoming an executive officer, Mr. Muehl received 7,500 stock options in consideration of his taking on additional responsibility following the planned retirement of Erle Mast as our CFO.

In August 2016, to encourage retention during a challenging period, and particularly to help ensure Clovis would retain employees through the planned launch of Rubraca, the compensation committee granted a one-time award of stock options and restricted stock units (RSUs) to any employee (other than Mr. Mahaffy, Dr. Rolfe and Ms. Ivers-Read) holding stock options with an exercise price of \$30.00 or greater. As a result, Mr. Hooks received 27,800 stock options and 13,900 RSUs and Mr. Muehl received 17,500 stock options and 8,750 RSUs.

In September 2016, Mr. Muehl received 20,000 stock options in connection with his promotion to Senior Vice President, Finance.

In December 2016 upon FDA approval of our New Drug Application (NDA) for rucaparib, Ms. Ivers-Read received a grant of 30,000 RSUs and Dr. Rolfe received a grant of 55,000 RSUs. Each grant is subject to time-based vesting in recognition of the approval and to encourage the executives' retention during an important time for the company.

See page 33 for details.

Extended Stock Option Exercise Periods

In recognition of Mr. Mast's exceptional service with the company and as further consideration for his continued compliance with his restrictive covenants following his retirement in March 2016, we extended the period following his retirement during which Mr. Mast could exercise his vested non-qualified stock options through March 31, 2017, the 12-month anniversary of his retirement.

Cash and Equity Retention Bonuses

In order to address morale and retention issues during a challenging period, and particularly to help ensure Clovis would retain key employees through the planned launch of Rubraca, the compensation committee granted a one-time cash and equity bonus to certain employees, none of which were executive officers of the company. Because each of Messrs. Muehl and

Table of Contents

Hooks were not executive officers at such time and were identified as key employees by the company, each of Messrs. Muehl and Hooks were granted a one-time cash retention bonus equal to \$50,000 and \$100,000, respectively, payable on the first regularly scheduled payroll date in March 2017 and February 2017, respectively, in each case, subject to the employee's continued employment through such date. In addition, as part of such program, in March 2016 Mr. Muehl received 5,000 stock options and 2,500 RSUs, to vest in two equal installments on March 1, 2017 and March 1, 2018, and in February 2016 Mr. Hooks received 10,000 stock options, to vest in two equal installments on February 1, 2017 and February 1, 2018. In the event Mr. Muehl's or Mr. Hooks's employment is terminated by the company without misconduct (as defined in the 2011 Plan), the vesting of their respective options and RSUs is accelerated in full.

See page 33 for details.

**Key 2017
Compensation
Decisions**

Base Salary

Effective March 1, 2017, consistent with the annual budget increase for all employees and, other than with respect to Ms. Ivers-Read and Dr. Rolfe, to align their base salary compensation with the 50th percentile of peer group companies, Mr. Mahaffy received a base salary increase of 14.7%, Mr. Muehl received a base salary increase of 13.6%, Ms. Ivers-Read received a base salary increase of 3.0%, Dr. Rolfe received a base salary increase of 8% and Mr. Hooks received a base salary increase of 11.1%. See page 31 for details.

Equity Compensation

On March 27, 2017, among other equity grants to our executive officers, we granted Mr. Mahaffy 75,000 stock options, which vest only upon FDA approval of a supplemental NDA for second-line maintenance therapy for rucaparib based on data from the ARIEL3 trial. Mr. Mahaffy received an additional 75,000 stock options that will vest over four years. See page 34 for details.

Updated Executive Compensation Peer Group

To ensure that our executive compensation program remains competitive in the biotechnology and pharmaceuticals industry, we updated our peer group used for benchmarking executive compensation practices to reflect changes in our market capitalization and by adding late-stage pre-commercial and commercial biopharmaceutical companies. See page 26 for details.

Pay-for-Performance Focus

Aligning Pay with Performance

Our executive compensation program is designed to link pay and performance an important principle of our compensation philosophy whereby executives earn target compensation only to the extent we achieve our company-wide performance goals, some of which are short-term, while others take several years to achieve.

Our success depends largely on the contributions of motivated, focused and energized people all working to achieve our company-wide performance goals. Therefore, our annual and long-term incentive plans each have performance measures that apply to our 2016 named executive officers to foster teamwork and maximize our performance. The annual incentive plan also takes into account individual performance and contributions.

Performance-Based Compensation

To the extent target performance measures are not achieved, or they are exceeded, the named executive officers generally will earn compensation below or above the target total compensation, respectively, supporting our pay-for-performance objectives.

Table of Contents

	Annual Performance		
	Bonus	Equity Compensation	Equity Compensation
	Short-Term Incentive	Long-Term Incentive	Long-Term Incentive
	(Cash)	(Stock Options)	(Restricted Share Units)
Objective	Short-term operational and financial business priorities	Longer-term strategic goals and stock price appreciation	Longer-term strategic goals and stock price appreciation
Time Horizon	1 Year	2 or 4 Years	2 or 4 Years
Metrics	Achievement of strong company-wide and individual performance	Stock price appreciation	Stock price appreciation

In order to support our pay-for-performance philosophy and our achievement of strong company-wide performance, the majority of the total compensation our CEO receives is performance-based, as shown below:

President and Chief Executive Officer Pay

This section presents supplemental information to the 2016 Summary Compensation Table that begins on page 36. The following chart shows realizable long-term compensation paid to our CEO for the past three years and indicates what we believe are more accurate statements of our CEO's actual compensation value as compared to the compensation reported in the 2016 Summary Compensation Table, which is tied to the grant date fair value of awards.

The primary difference between the total amounts shown in the chart below (realizable pay) and in the 2016 Summary Compensation Table (reported pay) is that the chart below reflects the intrinsic value of our CEO's equity awards based on our closing stock price on December 30, 2016 of \$44.42 per share (2016 Values), as opposed to the reported pay in the 2016 Summary Compensation Table, which represents the grant date fair value of the applicable stock awards. Because the 2016 Values are based on the market value of our stock at year end, we believe the 2016 Values more accurately reflect the current value of the long-term compensation we have paid to our CEO. In addition, reported pay for our CEO in the 2016 Summary Compensation Table decreased between 2015 and 2016 primarily due to him waiving his base salary for part of the year.

The chart below underscores the difference between grant date fair value and the 2016 Values of the annual long-term compensation earned by our CEO for the years 2014-2016, as applicable. Since the vast majority of our CEO's reported pay represents potential pay, the chart below highlights the alignment of our at-risk compensation with the value of our stock and hence, the long-term interests of our CEO with those of our

Table of Contents

stockholders. For 2016, our CEO's realizable compensation is less than the grant date fair value compensation, reinforcing the performance orientation of our program and the alignment of interests between our executives and our stockholders.

Additionally, our CEO, who is a founder, continues to hold all of the equity he has been granted since our IPO apart from small gifts to his children and to a donor-advised fund for the purpose of charitable contributions, reflecting his long-term commitment to building value for our stockholders. Because of this, our CEO has not realized any gains from any equity-based compensation, as evidenced in his realized pay in the chart below.

Realizable pay includes:

Base Salary: Yearly pay based on role, skills, experience and performance in the role

Annual Performance Bonus: Annual cash award payout amounts for 2014, 2015 and 2016

Equity Compensation: Represents the current intrinsic value of the unvested stock granted during that year using the stock price on December 31, 2016

Governance of Executive Compensation

Role of the Compensation Committee

The compensation committee of our board of directors is responsible for determining appropriate compensation levels and arrangements for our named executive officers, ensuring they are consistent with our compensation philosophy and objectives, and support the successful recruitment, development and retention of executive talent and leadership required to achieve our business objectives. In making this determination, the

Realized pay includes:

Base Salary: Yearly pay based on role, skills, experience and performance in the role

Annual Performance Bonus: Annual cash award payout amounts for 2014, 2015 and 2016

Equity Compensation: Gains received from exercised stock options

The compensation committee reviews all the components of annual compensation (including base salary, annual performance bonus and equity compensation) for the named executive officers and determines that each individual's total compensation is reasonable and consistent with our compensation philosophy.

compensation committee considers each named executive officer's individual performance and contributions to our growth and success, as well as overall achievement of performance goals. The compensation committee also considers the recommendations of our CEO, market data provided by the compensation committee's external independent compensation consultant and additional factors, such as the named executive officer's operating responsibilities, experience level, retention risk, tenure and performance in the position.

- 23 -

Table of Contents

In determining the levels and mix of compensation, our compensation committee has not generally relied on formulaic guidelines, but rather has maintained a flexible approach to compensation determinations, which allows it to adapt the various elements of compensation to motivate individual executives and achieve our specific strategic and financial goals.

The compensation committee then approves, with any modifications it deems appropriate, base salaries, target annual performance bonus opportunities, equity compensation opportunities and grants for our named executive officers.

In reviewing our compensation program, the compensation committee considers whether the programs encourage unnecessary or excessive risk taking that could have a material adverse effect on us and has concluded that they do not.

Role of the President and Chief Executive Officer

Our CEO periodically reviews each named executive officer's overall performance and makes recommendations to the compensation committee on the elements of the named executive officers' compensation (other than for the CEO). These recommendations are based on our CEO's personal review of the other named executive officers' performance, job responsibilities and importance to our overall business strategy, as well as our compensation philosophies. Although these recommendations are given significant weight, the compensation committee retains full discretion when determining compensation.

The compensation package for our CEO is determined by the compensation committee in its sole discretion. Our CEO does not participate in discussions regarding his compensation.

Role of the Compensation Consultant

The compensation committee retains ultimate responsibility for compensation-related decisions. The compensation committee has the power to hire and fire independent compensation consultants, legal counsel, and financial or other advisors as it may deem necessary to assist it in the performance of its duties and responsibilities, without consulting or obtaining the approval of our senior management. The compensation committee

The compensation committee has assessed the independence of Radford pursuant to SEC and NASDAQ rules and concluded that no conflict of interest exists that would prevent Radford from independently representing the compensation committee.

recognizes the importance of objective, independent expertise and advice in carrying out its responsibilities. To add rigor in the review process and to inform the compensation committee of market trends, the compensation committee engages the services of Radford, an Aon Hewitt company, to review and advise on our compensation practices and to assess whether our compensation program is competitive and supports the compensation committee's goal to align the interests of executive officers with those of stockholders. Radford also provides market data directly to the compensation committee, which the compensation committee references when determining compensation for executive officers.

The compensation committee has the sole authority to approve the independent compensation consultant's fees and terms of the engagement. The compensation committee regularly reviews its relationship with, and assesses the independence of, Radford to ensure executive compensation consulting independence.

The process includes a review of the services Radford provides, the quality of those services, and fees associated with the services during the year.

Table of Contents

Executive Compensation Peer Group

We believe that stockholders are best served when the compensation packages of senior executives are competitive but fair. By fair, we mean that the executives will be able to understand that the compensation package reflects their market value and their personal contribution to the business. To help ensure we provide our named executive officers with fair and market-competitive compensation and to support retention of our key leaders, we annually review compensation we offer our executives against executives within our peer group. Our 2016 peer group consisted of companies determined to be:

Biotechnology and pharmaceutical companies and

Generally of a similar size to us:

Phase III and recently commercial companies with generally less than \$100 million in annual revenue that meet market capitalization requirement to match recruiting market;

Market capitalization generally between \$400 million and \$4 billion (approximately 0.3 to 3 times our market capitalization); and

Generally less than 300 employees.

These groups are regularly reviewed by our compensation committee with consideration given to our strategy and the advice of our compensation committee's independent advisor.

Our compensation committee approved the following 22 companies as part of our peer group for 2016:

2016 Executive Compensation Peer Group

ACADIA Pharmaceuticals, Inc.	Geron Corporation	New Link Genetics
Anacor Pharmaceuticals, Inc.	ImmunoGen	Portola Pharmaceuticals
ARIAD Pharmaceuticals Inc.	Infinity Pharmaceuticals	Puma Biotechnology

Array BioPharma	Insmed ¹	Seattle Genetics ¹
Celldex Therapeutics	Intercept Pharmaceuticals	Synergy Pharmaceuticals ¹
Cempra ¹	MacroGenics ¹	TESARO
Dynavax Technologies ¹	Merrimack Pharmaceuticals	Ultragenyx Pharmaceutical
Exelixis ¹		

¹ Added as new compensation peer for 2016. In selecting peers, our compensation committee generally seeks to maintain consistency from year to year, other than for events that potentially call for the immediate elimination of a peer group member. In 2016, new compensation peers were added to replace removed peers that no longer met the criteria set forth above.

The compensation committee has approved the 19 companies in the table below as our peer group for 2017. Our updated peer group includes companies with the following criteria:

Market capitalization in the range of \$1 billion to \$7.5 billion (approximately 0.3 to 3 times the company's market capitalization);

Commercial companies with revenues under \$300 million (or recent NDAs with breakthrough designation by the FDA); and

Generally between 300 and 500 employees.

Table of Contents

Our 2017 peer group is comprised of:

2017 Executive Compensation Peer Group		
ACADIA Pharmaceuticals, Inc.	Momenta Pharmaceuticals ¹	Seattle Genetics
Array BioPharma	Nektar Therapeutics ¹	Supernus Pharmaceuticals ¹
Exelixis	Neurocrine Biosciences ¹	TESARO
Halozyne Therapeutics ¹	Pacira Pharmaceuticals ¹	The Medicines Company ¹
Intercept Pharmaceuticals	Puma Biotechnology	Theravance Biopharma ¹
Ionis Pharmaceuticals ¹	Repligen ¹	Ultragenyx Pharmaceutical, Inc.
Ironwood Pharmaceuticals ¹		

¹ Added as new compensation peer for 2017. New compensation peers were added to replace removed peers that no longer met the criteria set forth above.

Targeting Compensation to Market

The compensation committee believes that targeting compensation for each executive between the 50th and 75th percentiles of their counterparts in our publicly-traded peer companies helps achieve our compensation objectives and will better position us to achieve our goals.

Using Peer Group Data to Set Target Opportunity

In setting 2016 compensation, the compensation committee reviewed the market data for our peer group and compared each named executive officer's base salary, target annual performance bonus and equity compensation value, separately and in the aggregate, to amounts paid to similarly-situated executives at our peer companies.

Compensation for each executive may vary from this range depending on other factors, such as internal pay equity amongst our named executive officers or levels of authority, responsibility and experience of our named executive officers that exceed the norms for individuals holding comparably-titled positions at other companies.

Other Key Features of Our Executive Compensation Program

As we look to the future of the company, we have adopted policies to help drive sustainable growth by further aligning the financial interests of our executives and stockholders with long-term stock price performance, which will help limit excessive risk-taking and executive misconduct through stock ownership guidelines, minimum holding requirements, a clawback policy and an enhanced anti-hedging policy, as outlined below.

Stock Ownership Guidelines

Our stock ownership guidelines require all executive officers to hold a minimum number of shares of our stock while serving as an executive officer. The guidelines are intended to further align the interests of executive management with those of our stockholders by requiring executives to be subject to the same long-term stock price volatility our stockholders experience. The minimum threshold is based on a multiple of base compensation, equal to three times base salary for our CEO and one times base salary for all other executive officers.

When determining whether the executive officers have met the minimum threshold requirements under the policy, calculations include all shares held outright by the executive and any vested equity awards. Each

Table of Contents

executive initially has five years in order to meet his or her minimum ownership threshold (and one year after a salary increase). During this five-year phase-in period, the executive is not allowed to sell more than 50% of any vested equity awards until he or she has met the applicable minimum threshold. The policy is administered and monitored by our Principal Financial Officer under the direction of the compensation committee. Currently, each of our named executive officers is in compliance with our stock ownership guidelines.

Minimum Holding Requirements

All new equity awards are subject to minimum holding requirements. This requires all executive officers to hold any shares obtained upon the exercise of a stock option or the vesting or settlement of other share-based awards for at least six months, except as necessary to cover the exercise price, taxes and broker commissions.

Clawback Policy

We maintain specific provisions regarding the recovery (clawback) of awards to deter certain types of conduct, including conduct that could affect the accuracy of our financial statements. If the board determines that an executive officer has engaged in detrimental conduct that directly or indirectly results in a material misstatement in our financial statements or performance metrics, which affects the executive officer's compensation, the board of directors may, in its discretion, seek reimbursement of any portion of performance-based equity awards earned by or incentive cash compensation paid or awarded to the executive that is greater than what would have been earned by, paid or awarded to the executive if calculated based on the restated financial statements or performance metrics. If the board of directors determines that it is appropriate to recoup incentive cash compensation or performance-based equity awards from an executive officer under this policy, the board of directors will, in its sole discretion, determine the following:

The amount of incentive based cash compensation or equity compensation provided to the executive officer that is subject to recoupment, and

The method of recoupment, including whether to seek the return of incentive-based compensation already paid or to withhold or otherwise recoup (totally or partially) compensation that has not vested or has not been paid.

Anti-Hedging and Anti-Pledging Policies

Our Insider Trading Policy prohibits hedging, pledging, short sales and transactions involving puts, calls and other derivative securities on an exchange by any employee or director.

Impact of Accounting and Tax Requirements on Compensation

The compensation committee periodically reviews the potential consequences of Section 162(m) of the Internal Revenue Code (which generally disallows a tax deduction to public companies for compensation in excess of \$1,000,000 paid to certain named executive officers) with respect to the elements of our compensation program; however, given that the impact of Section 162(m) on taxes currently payable by us is mitigated by our net operating loss carryforwards, the compensation committee has not limited compensation to those levels or types of compensation that would be deductible by us.

Establishing Say-on-Pay Vote

We are committed to soliciting and considering stockholder input as we evaluate the design of our executive compensation programs and the specific compensation decisions for each of our named executive officers.

In June 2012, we adopted a triennial approach to stockholder advisory votes on the compensation of our named executive officers (a say-on-pay vote). Over 75% of our stockholders approved the compensation of our named

Table of Contents

executive officers in 2012, and over 76% of our stockholders approved the compensation of our named executive officers in 2015. In 2018, we will hold our next scheduled say-on-pay vote to give stockholders the opportunity to provide input on our executives' compensation.

The members of our compensation committee favor a strong pay-for-performance approach to executive compensation and value stockholder feedback. In response to the 2015 say-on-pay vote, our compensation committee, our board of directors and management reviewed our compensation and governance practices and engaged with consultants and advisors. Based on this review, the compensation committee determined no changes to our compensation programs were necessary at that time.

Table of Contents**Elements of the Executive Compensation Program**

Our executive compensation program is designed to align the interests of our named executive officers and stockholders and to encourage both personal and collective contributions to support our growth. The following chart highlights the key elements of our executive compensation program and how each is linked to program objectives.

	Type of Compensation	Link to Program Objectives
Base Salary	Cash	Fixed level of cash compensation to support attraction and retention of key executives in a competitive marketplace
Annual Performance Bonus	Cash	Allows us to pay our executives competitively with compensation levels in the biopharmaceutical market Target cash incentive opportunity (set as a percentage of base salary) that encourages executives to achieve strong annual company-wide performance
Equity Compensation	Stock Options and RSUs	Assists in retaining, attracting and motivating employees in the near term Focuses executives on achievement of long-term company strategic goals and total stockholder return, thereby creating long-term stockholder value (pay-for-performance) Two- and four-year vesting promotes retention, helping to maintain a stable, continuous management team Named executive officers, similar to all employees, can participate in the Employee Stock Purchase Plan to purchase our ordinary shares at a discount on a tax-qualified basis through payroll deductions Promotes ownership in the company

**Retirement
Benefits**

Benefit Named executive officers participate in the 401(k) plan available to all employees

Retirement benefits are a standard element of a total rewards package that helps attract and retain executive talent

Other Benefits

Benefit Named executive officers participate in the benefit plans available to all employees, including health benefits and taxable life insurance premiums (also applicable to all employees)

Benefit plans are a standard element of a total rewards package that helps attract and retain executive talent

Perquisites are limited in amount and the compensation committee limits eligibility and use; named executive officers receive supplemental long-term disability coverage

**Severance and
Double Trigger
Change of Control
Agreements**

Benefit Retention bonuses payable subject to continued employment with the company

Helps ensure named executive officers remain focused on creating sustainable performance in case of personal uncertainties or risk of job loss

Provides confidentiality, non-compete and non-solicit protections

Table of Contents

Analysis of 2016 Compensation Decisions

Compensation packages for our named executive officers generally consist of base salary, bonus programs and equity compensation. In determining the levels and mix of compensation, we have not generally relied on formulaic guidelines, but rather have maintained a flexible approach to compensation determinations based on specific strategic and financial goals deemed important to our long-term success. We believe that the relationship of fixed to performance-based compensation is properly balanced and provides us with an effective means to attract, motivate and retain our named executive officers, as well as reward them for increases in the value of our common stock.

Base Salary

Base salaries for the named executive officers are intended to reflect their skill set, experience, role and responsibilities. The compensation committee initially determines base salary for named executive officers at the time of their appointment based on their position. The compensation committee periodically reviews base salaries for the named executive officers and may make adjustments based on individual performance, overall company performance and, when appropriate, to maintain consistency with our compensation objectives, including being market competitive.

Establishing Base Salaries

When establishing base salaries for named executive officers, the compensation committee considers an initial guideline between the 50th and 75th percentiles of the general industry and peer company data for comparable roles. Individual and company performance are also considered.

2016 Base Salary Decisions

In order to provide our named executive officers with base salaries that are competitive with our publicly-traded peer companies, base salaries for our named executive officers, other than Messrs. Mahaffy and Mast, were increased effective March 1, 2016. Ms. Ivers-Read received a base salary increase of 3%. Also, effective March 1, 2016, Dr. Rolfe received an increase of 11.5% to align her salary with the 50th percentile of the company's peer group. In addition, Mr. Hooks received base salary increases totaling 10.8% in connection with his promotion to Chief Commercial Officer. Mr. Muehl received an increase of 11.9% in connection with his promotion to Senior Vice President, Finance. Mr. Mast did not receive an increase as his retirement had previously been announced.

In April 2016, based on his recommendation to the compensation committee and the committee's review of the company's operating performance, Mr. Mahaffy voluntarily waived his right to receive any base salary in excess of \$1 (plus the cost of any employee-paid premiums for health and welfare benefits) until the FDA approved the commercial distribution, sale or marketing of rucaparib, Mr. Mahaffy retires, or the company undergoes a change in control. Upon the FDA's approval of rucaparib in December 2016, Mr. Mahaffy's base salary was reinstated to its normal rate.

- 30 -

Table of Contents

The following table lists the compensation of our named executive officers for 2015 and 2016.

	2015 Salary	2016 Base Salary	
		2016 Salary	Percent Change
Patrick J. Mahaffy	\$ 566,500	\$ 566,500 ¹	0%
Daniel W. Muehl	\$ 295,000	\$ 330,000 ²	11.9%
Gillian C. Ivers-Read	\$ 412,000	\$ 424,360 ³	3%
Lindsey Rolfe	\$ 390,000	\$ 435,000 ³	11.5%
C. Dale Hooks	\$ 325,000	\$ 360,000 ⁴	10.8%
Erle T. Mast	\$ 412,000	\$ 412,000 ⁵	0%

¹ Mr. Mahaffy earned a base salary at an annual rate of \$566,500 from January April 2016, at which time he voluntarily waived his right to receive any salary in excess of \$1 (plus the cost of any employee-paid premiums for health and welfare benefits) until the approval by the FDA to commercially distribute, sell or market rucaparib or other events. Mr. Mahaffy's salary was reduced to \$1 until December 2016, at which time it was reinstated to \$566,500.

² Mr. Muehl received a significant base salary increase in connection with his promotion to Senior Vice President, Finance.

³ Ms. Ivers-Read received a base salary increase of 3% and Dr. Rolfe received an increase of 11.5%.

⁴ Mr. Hooks received a significant base salary increase in connection with his promotion to Chief Commercial Officer.

⁵ Mr. Mast earned a base salary at an annual rate of \$412,000 from January March 2016, at which time he retired.

2017 Base Salary Decisions

Effective March 1, 2017, base salaries of our executive officers were increased, generally to align base salaries with the 50th percentile of our peer group, other than in the cases of Ms. Ivers-Read, who was already at the 75th percentile, and Dr. Rolfe, who was already at the 50th percentile but received a cost-of-living increase. The following table lists the compensation of our named executive officers for 2016 and 2017.

	2016 Salary	2017 Base Salary	
		2017 Salary	Percent Change
Patrick J. Mahaffy ¹	\$ 566,500	\$ 650,000	14.7%
Daniel W. Muehl	\$ 330,000	\$ 375,000	13.6%
Gillian C. Ivers-Read	\$ 424,360	\$ 437,132	3.0%
Lindsey Rolfe	\$ 435,000	\$ 470,000	8.0%
C. Dale Hooks	\$ 360,000	\$ 400,000	11.1%

¹ Mr. Mahaffy earned a base salary at an annual rate of \$566,500 from January April 2016, at which time he voluntarily waived his right to receive any salary in excess of \$1 (plus the cost of any employee-paid premiums for health and welfare benefits) until the approval by the FDA to commercially distribute, sell or market rucaparib or other events. Mr. Mahaffy's salary was reduced to \$1 until December 2016, at which time it was reinstated to \$566,500. The percent change for Mr. Mahaffy represents the change from his salary of \$566,500 that would have

been paid to him in 2016 absent his waiver to his actual 2017 base salary.

- 31 -

Table of Contents**Annual Performance Bonus**

Our annual performance bonus provides named executive officers with the opportunity to earn rewards based on the achievement of strong corporate-wide performance.

2016 Annual Performance Bonus Decisions

During the first quarter of 2017, the compensation committee reviewed our performance against our 2016 corporate goals, as well as the overall progress of the company. The 2016 corporate-wide goals included:

2016 Corporate Goals

FDA approval of the commercial distribution, sale or marketing of rucaparib

U.S. commercial launch of Rubraca

Realizing cost savings while successfully retaining the U.S. sales force to enable us to rapidly launch Rubraca following FDA approval

Submitting an MAA for rucaparib to the European Medicines Agency

Entering into a long-term manufacturing and supply agreement with Lonza in support of rucaparib's anticipated U.S. commercial launch

Completing target enrollment in the ARIEL3 pivotal maintenance study for Rubraca

Our named executive officers are measured on both corporate and individual performance, with a weighting of 75% and 25% respectively.

For 2016 performance, the compensation committee determined to pay bonus awards in an amount equal to 150% of target levels for Mr. Mahaffy, Ms. Ivers-Read, Dr. Rolfe and Messrs. Hooks and Muehl. Mr. Mast did not receive a bonus award for 2016 performance, as he retired from the company prior to bonus payout.

Linking Compensation to Performance

The compensation committee believes that linking pay to performance will motivate our executives to achieve the greatest possible returns for our stockholders.

Status
COMPLETED
COMPLETED
COMPLETED
COMPLETED
COMPLETED
COMPLETED

	2016 Annual Incentive (paid in 2017)		
	Target as a % of Base Salary	Target Award Opportunity	Actual Amount Awarded
Patrick J. Mahaffy	65%	\$ 368,225	\$ 522,338
Daniel W. Muehl	40%	\$ 113,866 ¹	\$ 170,799
Gillian C. Ivers-Read	45%	\$ 190,962	\$ 286,443
Lindsey Rolfe	45%	\$ 195,750	\$ 293,625
C. Dale Hooks	40%	\$ 144,000	\$ 216,000

¹ Based on base salary of \$299,425 and bonus target of 35% for the first eight months of 2016 and base salary of \$330,000 and bonus target of 40% for the last four months of 2016.

Equity Compensation

We maintain the Clovis Oncology, Inc. 2011 Stock Incentive Plan, or the 2011 Plan, for our named executive officers. We believe stock option awards provide a motivational tool because they have value only to the extent the stock price on the date of exercise exceeds the exercise price on the grant date. In order to align the interests of our named executive officers with those of our stockholders, as well as to provide sufficient retention incentives to our executives, the compensation committee deemed it appropriate to grant stock options and restricted stock units to our named executive officers.

In determining the amount of equity to grant our named executive officers, the compensation committee took into account both the grant date fair value and the actual realizable value of the options and restricted stock units then outstanding. We believe realizable value is a more accurate statements of our named executive officers actual compensation value as compared to the grant date fair value of these awards.

Table of Contents***2016 Equity Compensation Decisions***

In February 2016, Mr. Hooks received 10,000 stock options in connection with his promotion to Chief Commercial Officer. 25% of the award vested on the first anniversary of the grant, and the remaining 75% vests in equal monthly installments over the three years following the first anniversary.

In March 2016, and prior to becoming an executive officer, Mr. Muehl received 7,500 stock options in consideration of his taking on additional responsibility following the planned retirement of Erle Mast as our CFO. 25% of this award vested on the first anniversary of the grant, and the remaining 75% will vest in equal monthly installments over the three years following the first anniversary.

In August 2016, the compensation committee granted a one-time award of stock options and RSUs to any employee (other than Mr. Mahaffy, Dr. Rolfe and Ms. Ivers-Read) holding stock options with an exercise price of \$30.00 or greater. As a result, Mr. Hooks received 27,800 stock options (equal to 50% of his stock options with an exercise price above \$30.00) and 13,900 RSUs (equal to 25% of his stock options with an exercise price above \$30.00). In addition, Mr. Muehl received 17,500 stock options (equal to 50% of his stock options with an exercise price above \$30.00) and 8,750 RSUs (equal to 25% of his stock options with an exercise price above \$30.00). 25% of each award will vest on the first anniversary of the grant, and the remaining 75% will vest in equal monthly installments (quarterly installments for RSUs) over the three years following the first anniversary.

In September 2016, Mr. Muehl received an additional grant of 20,000 stock options in connection with his promotion to Senior Vice President, Finance in September 2016. 25% of this award will vest on the first anniversary of the grant, and the remaining 75% will vest in equal monthly installments over the three years following the first anniversary.

In December 2016 upon FDA approval of our NDA for rucaparib, Ms. Ivers-Read received a grant of 30,000 RSUs and Dr. Rolfe received a grant of 55,000 RSUs in recognition of the approval, to encourage their retention during an important time for the company, and to align their equity compensation with the 50th percentile of peer group companies. 25% of the RSUs will vest on the first anniversary of the grant, and the remaining 75% vests in quarterly installments over the three years following the first anniversary.

Messrs. Mahaffy and Mast did not receive stock option grants in 2016. In addition, during 2016, each of Mr. Mahaffy and Ms. Ivers-Read voluntarily forfeited 25,000 and 8,750 stock options, respectively, granted to them in 2015 that were scheduled to vest upon the approval by the FDA to commercially distribute, sell or market rociletinib.

The following table provides information about the number of stock options and RSUs granted in 2016, and the value of those stock options and RSUs:

2016 Equity Awards			
Number of Stock Options	Date of Grant	Fair Value of Stock	Realizable Value (as of)
		Number of RSUs	Value of RSUs

		Options¹			12/31/16²			
Daniel W. Muehl	50,000	\$	824,799	11,250	\$	247,313	\$	1,609,025
Gillian C. Ivers-Read	0	\$	0	30,000	\$	1,214,000	\$	1,332,600
Lindsey Rolfe	0	\$	0	55,000	\$	2,226,400	\$	2,443,100
C. Dale Hooks	57,800	\$	908,072	13,900	\$	315,947	\$	1,941,320

¹ Grant date fair value is a value determined at the time of grant for accounting purposes, which is based on Black-Scholes modelling to value options.

² The intrinsic monetary value of the grant to the named executive officer, assuming all the shares vest, based on December 31, 2016 closing share price. Because the realizable values are based on the market value of our stock at year end, we believe these values more accurately reflect the current value of the long-term compensation we have paid to our named executive officers.

Table of Contents**2017 Equity Compensation Decisions**

In March 2017, we resumed the annual equity incentive grants for our named executive officers. The following table provides information about the number of stock options and RSUs awarded, and the value of those stock options and RSUs:

	2017 Equity Awards			
	Number of Stock Options	Grant Date Fair Value	Number of RSUs	Value of RSUs
Patrick J. Mahaffy	150,000 ²	\$ 7,587,660	0	N/A
Daniel W. Muehl	15,000	\$ 758,766	7,500	\$ 512,325
Gillian C. Ivers-Read	20,000	\$ 1,011,688	10,000	\$ 683,100
Lindsey Rolfe	20,000	\$ 1,011,688	10,000	\$ 683,100
C. Dale Hooks	15,000	\$ 758,766	7,500	\$ 512,325

¹ Grant date fair value is a value determined at the time of grant for accounting purposes, which is based on Black-Scholes modelling to value options.

² Mr. Mahaffy received 75,000 stock options, which vest only upon FDA approval of a supplemental NDA for second-line maintenance therapy for Rubraca based on data from the ARIEL3 trial, and an additional 75,000 stock options that will vest over four years.

Retirement Savings Programs

In 2016, we provided retirement benefits to our named executive officers through the Clovis Oncology, Inc. 401(k) plan, a defined contribution retirement savings plan. The named executive officers participate in the plan on the same terms and conditions as our other employees. We make matching contributions to the account of each eligible employee under the 401(k) plan of 100% on the first 4% of gross wages that an employee contributes to his or her account. In 2016, Mr. Mahaffy received matching contributions of \$7,800 to his 401(k) plan, while Mr. Mast received \$5,200. Ms. Ivers-Read, Mr. Hooks and Mr. Muehl each received \$10,600. Dr. Rolfe did not receive matching contributions in 2016.

The Clovis Oncology, Inc. 401(k) plan supports an important part of our executive compensation program objectives: retention.

Other Benefits

In 2016, all of the named executive officers were eligible to participate in a number of broad-based benefit programs, including health benefits and a life insurance benefit equal to two times their base salary, subject to an overall cap. Because the U.S. Internal Revenue Code imputes income on life insurance benefits above a threshold (\$50,000 in 2016), we include an amount of income attributable to the taxable insurance premiums we pay. This life insurance benefit is provided to all employees and consequently applies to our named executive officers.

We maintain an employee stock purchase plan, the ESPP, which provides our employees, including our named executive officers, with an opportunity to purchase our ordinary shares at a discount on a tax-qualified basis through payroll deductions. The ESPP is designed to qualify as an employee stock purchase plan under Section 423 of the Internal Revenue Code.

The named executive officers also received certain perquisites, including supplemental long-term disability coverage, which we believe are necessary in light of the competitive market for talent in our industry. The total cost of these benefits is a small percentage of each named executive officers total compensation. The value of these benefits is reflected in the All Other Compensation column in the 2016 Summary Compensation Table.

In order to address morale and retention issues during a challenging period, and particularly to help ensure Clovis would retain key employees through the NDA submission, FDA review process, and planned launch of Rubraca,

Table of Contents

the compensation committee granted a one-time cash and equity bonus to certain employees, none of which were executive officers of the company. Because each of Messrs. Muehl and Hooks were not executive officers at such time and were identified as key employees by the company, each of Messrs. Muehl and Hooks were granted a one-time cash retention bonus equal to \$50,000 and \$100,000, respectively, payable on the first regularly scheduled payroll date in March 2017 and February 2017, respectively, in each case, subject to the employee's continued employment through such date. In addition, as part of such program, in March 2016 Mr. Muehl received 5,000 stock options and 2,500 RSUs, to vest in two equal installments on March 1, 2017 and March 1, 2018, and in February 2016 Mr. Hooks received 10,000 stock options, to vest in two equal installments on February 1, 2017 and February 1, 2018. In the event Mr. Muehl's or Mr. Hooks's employment is terminated by us without misconduct (as defined in the 2011 Plan), the vesting of their respective options and RSUs is accelerated in full.

Employment Agreements

We entered into substantially similar employment agreements (described in more detail below) with Mr. Mahaffy and Ms. Ivers-Read on August 24, 2011, with Dr. Rolfe on February 25, 2016, and with Mr. Hooks on February 1, 2016. With the assistance of our compensation consultants, the compensation committee determined that it was advisable to enter into employment agreements or offer letters with each executive with a title of executive vice president or higher to ensure that the compensation and benefits provided to such executives was competitive with our publicly-traded peer companies and to ensure that we have adequate protection in the form of restrictive covenants following a termination of employment. The employment agreements with each of our named executive officers (other than Mr. Muehl) also provide for severance payments and benefits upon certain qualifying terminations of employment. For additional information about these employment agreements, see Narrative Disclosure Relating to Summary Compensation Table and Grant of Plan Based Awards Table below.

Report of the Compensation Committee

Our compensation committee has reviewed and discussed with management the Compensation Discussion and Analysis set forth in this proxy statement. Based on such review and discussions, our compensation committee has recommended to the board of directors that the Compensation Discussion and Analysis be included in this proxy statement and in the annual report on Form 10-K for the year ended December 31, 2016, filed by us with the SEC.

Respectfully submitted,

The Compensation Committee of the Board of Directors

M. James Barrett

James C. Blair

Thorlef Spickschen

Ginger Graham

The material in this report is not soliciting material, shall not be deemed filed with the SEC and shall not to be incorporated by reference in any filing of Clovis Oncology, Inc. under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

Table of Contents**Summary Compensation Table**

The following table shows the compensation of our principal executive officer, our principal financial officer and our other named executive officers for the years ended 2016, 2015 and 2014.

Name and principal position⁽¹⁾	Year	Salary (\$)⁽²⁾	Bonus (\$)⁽³⁾	Option Awards (\$)⁽⁴⁾	Stock Awards (\$)⁽⁵⁾	All Other Compensation (\$)⁽⁶⁾	Total (\$)
Patrick J. Mahaffy President and Chief Executive Officer	2016	223,563	552,338			12,718	788,619
	2015	563,750		5,091,720		15,522	5,670,992
	2014	544,167	357,500	9,206,220		15,146	10,123,033
Daniel W. Muehl Senior VP of Finance ⁽⁸⁾	2016	308,879	170,799	824,799	247,313	12,679	1,564,469
Gillian C. Ivers-Read EVP of Technical Operations and Chief Regulatory Officer	2016	422,300	286,443		1,214,400	26,423	1,949,566
	2015	410,000	61,182	1,782,102		26,423	2,279,707
	2014	395,217	180,000	3,222,177		26,093	3,823,487
Lindsey Rolfe EVP of Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer ⁽⁷⁾	2016	427,500	293,625		2,226,400	3,796	2,951,321
	2015	350,409	57,915	2,590,701		71,815	3,070,839
	2014						
C. Dale Hooks Senior VP and Chief Commercial Officer ⁽⁸⁾	2016	356,250	216,000	908,072	315,947	13,019	1,809,288
Erle T. Mast Former EVP and Chief Financial Officer	2016	135,952				6,382	142,334
	2015	410,000	61,182	1,782,102		15,522	2,268,806
	2014	395,217	180,000	3,222,177		15,146	3,812,540

(1) The positions reported for each named executive officer are the positions held on December 31, 2016. Mr. Muehl was appointed as our Senior Vice President in August 2016, having previously served as Vice President of Finance. Mr. Hooks was appointed as our Senior Vice President and Chief Commercial Officer in March 2016, having previously served as Vice President of Sales. Mr. Mast retired from Clovis Oncology in March 2016, having previously served as our Executive Vice President and Chief Financial Officer. At the time of his retirement, Mr. Mast ceased to serve as our Principal Financial Officer and Principal Accounting Officer and Mr. Muehl began to serve as our Principal Financial Officer and Principal Accounting Officer.

(2) Amounts reported in this column reflect mid-year pay increases. For additional information, please see Compensation Discussion and Analysis Analysis of 2016 Compensation Decisions Base Salary above. In addition, amounts reported in this column for Mr. Mast reflect a base salary at an annual rate of \$412,000, earned from January through March 2016, at which time he retired. In addition, Mr. Mahaffy earned a base salary at an annual rate of \$566,500 from January through March 2016, at which time he voluntarily waived his right to receive any

- salary in excess of \$1 (plus the cost of any employee-paid premiums of health and welfare benefits) until the approval by the FDA to commercially distribute, sell or market rucaparib or other events. Mr. Mahaffy's salary was re-instated in December 2016 upon the Company's receipt of such approval by the FDA.
- (3) The amounts reported in this column represent the bonuses earned by each executive with respect to performance in 2016. Mr. Mast did not receive a bonus award for 2016 performance, as he retired from the company prior to bonus payout. For additional information, please see Compensation Discussion and Analysis Analysis of 2016 Compensation Decisions Annual Performance Bonus above.
- (4) Amount represents the aggregate grant date fair value of option awards granted to our named executive officers in 2016 computed in accordance with FASB ASC Topic 718. For a discussion of the assumptions

Table of Contents

made in the valuation, see Note 9 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016. The amounts above reflect our aggregate accounting expense for these awards and do not necessarily correspond to the actual value that will be recognized by the named executive officers. Amounts reported in this column for Mr. Mast also include \$381,096, calculated in accordance with FASB ASC Topic 718, as a result of the extended exercise period applicable to his options. For additional information, please see Compensation Discussion and Analysis Overview of 2016 Compensation Decisions and Actions above.

- (5) Amount represent the aggregate grant date fair value of restricted stock units, calculated in accordance with FASB ASC Topic 718, disregarding for this purpose the estimate of forfeitures related to service-based vesting conditions. The grant date fair value is calculated using the closing price of our common stock on the date of grant. See Note 9 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016, for a discussion of the assumptions used to calculate these values. The amounts above reflect our aggregate accounting expense for these awards and do not necessarily correspond to the actual value that will be recognized by the named executive officers.
- (6) The amounts reported in this column include the cost of the following perquisites and other benefits received by our named executive officers:

Mr. Mahaffy. The amount reported represents an employer matching contribution to our 401(k) plan equal to \$7,796, payment by us of taxable life insurance premiums equal to \$966, and supplemental long-term disability coverage.

Mr. Muehl. The amount reported represents an employer matching contribution to our 401(k) plan equal to \$10,600, payment by us of taxable life insurance premiums equal to \$966, and supplemental long-term disability coverage.

Ms. Ivers-Read. The amount reported represents an employer matching contribution to our 401(k) plan equal to \$10,600, payment by us of taxable life insurance premiums equal to \$4,356, and supplemental long-term disability coverage equal to \$11,467

Dr. Rolfe. The amount reported represents payment by us of taxable life insurance premiums equal to \$630, and supplemental long-term disability coverage.

Mr. Hooks. The amount reported represents an employer matching contribution to our 401(k) plan equal to \$10,600, payment by us of taxable life insurance premiums equal to \$966, and supplemental long-term disability coverage.

Mr. Mast. The amount reported represents an employer matching contribution to our 401(k) plan equal to \$5,233, payment by us of taxable life insurance premiums equal to \$242, and supplemental long-term disability coverage.

(7)

Dr. Rolfe was not a named executive officer prior to her appointment as EVP of Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer and, therefore, in accordance with SEC regulations, only compensation information for the 2016 fiscal year and the fiscal year in which she became a named executive officer is included in the Summary Compensation Table.

- (8) Messrs. Muehl and Hooks were not named executive officers until 2016 and, therefore, in accordance with SEC regulations, only compensation information for the fiscal year in which they became named executive officers are included in the Summary Compensation Table.

Table of Contents**Grant of Plan Based Awards Table**

The following table sets forth summary information regarding all grants of plan-based awards made to our named executive officers for the year ended December 31, 2016.

Name	Grant Date	All Other Option Awards: Number of Securities Underlying Option Awards (#)⁽¹⁾	Exercise Price or Base Price of Option Awards (\$/Sh)⁽³⁾	Grant Date Fair Value of Option Awards(\$)⁽⁴⁾	All Other Stock Awards: Number of Shares of Stock or Units (#)⁽⁵⁾	Grant Date Fair Value of Stock and Option Awards (\$)⁽⁷⁾
Patrick J. Mahaffy						
Daniel W. Muehl	3/1/2016	7,500	19.37	102,921		
	3/1/2016	5,000 ⁽²⁾	19.37	68,615		
	3/1/2016				2,500 ⁽⁶⁾	48,425
	8/25/2016	17,500	22.73	298,827		
	8/25/2016				8,750	198,888
	9/1/2016	20,000	23.59	354,436		
Gillian C. Ivers-Read	12/19/2016				30,000	1,214,400
Lindsey Rolfe	12/19/2016				55,000	2,226,400
C. Dale Hooks	2/1/2016	10,000	20.90	148,068		
	2/1/2016	10,000 ⁽²⁾	20.90	148,068		
	3/1/2016	10,000	19.37	137,229		
	8/25/2016	27,800	22.73	474,707		
	8/25/2016				13,900	315,947

- (1) Except as noted in Footnote 2 below, amounts reported in this column represent grants of options to purchase our common stock, twenty-five percent of which will vest on the one-year anniversary of the date of grant, and the remainder will vest in substantially equal installments over the 36 months immediately following such anniversary, subject to continued employment through such date.
- (2) Represent grants of options to purchase our common stock, fifty percent of which will vest on the one-year anniversary of the date of grant, and the remainder will vest on the second anniversary of the date of grant, subject to continued employment through such date.
- (3) The exercise price of the options was set at the fair market value of one share of our common stock at the time of the grant.
- (4) Amount represents the aggregate grant date fair value of option awards granted to our named executive officers in 2016 computed in accordance with FASB ASC Topic 718. For a discussion of the assumptions made in the valuation, see Note 9 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016.
- (5) Except as noted in Footnote 6 below, amounts reported in this column represent grants of restricted stock units, twenty-five percent of which will vest on the one-year anniversary of the date of grant, and the remainder will

- vest in substantially equal installments over the 12 quarters immediately following such anniversary.
- (6) Represent grants of restricted stock units, fifty percent of which will vest on the one-year anniversary of the date of grant, and the remainder will vest on the second anniversary of the date of grant, subject to continued employment through such date.
 - (7) Amount represent the aggregate grant date fair value of restricted stock units granted to our named executive officers in 2016, computed in accordance with FASB ASC Topic 718, disregarding for this purpose the estimate of forfeitures related to service-based vesting conditions. The grant date fair value is calculated using the closing price of our common stock on the date of grant. See Note 9 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016, for a discussion of the assumptions used to calculate these values.

Table of Contents

Narrative Disclosure Relating to Summary Compensation Table and Grant of Plan Based Awards Table

Employment Agreements with Messrs. Mahaffy and Hooks, Dr. Rolfe, and Ms. Ivers-Read

We are a party to employment agreements with Messrs. Mahaffy and Hooks, Dr. Rolfe and Ms. Ivers-Read. The agreements are substantially the same other than differences in base salary, target annual bonus percentages and severance. Prior to his retirement in March 2016, we were also party to a substantially similar employment agreement with Mr. Mast.

The employment agreements for Messrs. Mahaffy and Hooks, Dr. Rolfe and Ms. Ivers-Read provide for an annual base salary of no less than \$450,000, \$350,000, \$390,000, and \$350,000, respectively. Additionally, for 2016 the target annual bonuses were set at 65% of his annual base salary for Mr. Mahaffy, 45% of their respective annual base salaries for Dr. Rolfe and Ms. Ivers-Read and 40% of his annual base salary for Mr. Hooks.

In the event that a named executive officer's employment is terminated by us without just cause (as defined in the employment agreement) or by the executive for good reason (as defined in the employment agreement), the executive will, subject to his or her execution of a general release of claims and continued compliance with any restrictive covenants, be entitled to:

Any earned but unpaid bonus for the calendar year immediately preceding the calendar year of termination;

Continuation of his or her then-current base salary during the severance period; and

Payment of an applicable percentage (the percentage of employee health care premium costs covered by us as of the date of termination) of the executive's COBRA premiums during the severance period.

For purposes of the employment agreements, the term severance period generally means 9 months for Mr. Mahaffy and 6 months for Mr. Hooks, Dr. Rolfe, and Ms. Ivers-Read, except that the severance period will increase to 24 months for Mr. Mahaffy and 12 months for Mr. Hooks, Dr. Rolfe and Ms. Ivers-Read in the event that such termination occurs during the 12 months following a change in control (as defined in the employment agreement). Additionally, in the event that such termination occurs within 12 months following a change in control, the executives will also be entitled to (x) accelerated vesting of all outstanding equity awards, and (y) an amount equal to the executive's then-current target bonus, payable in equal monthly installments during the severance period. In such a circumstance, each named executive officer will also be entitled to a gross-up payment for payments that result in an excise tax imposed by Section 4999 of the Internal Revenue Code, subject to a maximum gross-up payment of \$2,000,000.

Following any termination of a named executive officer's employment, he or she will be subject to customary non-compete restrictions for 6 months (or in the case of Mr. Mahaffy, 9 months) and also a customary 12 month non-solicit period with respect to employees and customers. Dr. Rolfe is not subject to a non-compete restriction following her termination of employment in light of the prohibition on such agreements for employees employed in the state of California.

Offer Letter with Mr. Muehl

We are party to an offer letter with Mr. Muehl, which describes his basic compensation and benefit entitlements, including base salary, target annual bonus and participation in our stock plan and other employee benefit programs. Mr. Muehl's agreement does not provide for any severance upon a termination of employment.

Stock Plan

We maintain the 2011 Plan, pursuant to which 7,461,862 shares of our common stock are reserved for options outstanding and future grants to our employees, consultants and directors as of December 31, 2016. We adopted the 2011 Plan to afford our compensation committee with more flexibility by allowing grants of a wide variety of equity awards to our key employees, directors and consultants, including incentive and nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other

Table of Contents

stock-based awards. The 2011 Plan is designed to assist us in attracting, retaining, motivating and rewarding key employees, directors, and consultants, and promoting the creation of long-term value for our stockholders by closely aligning the interests of the participants with those of our stockholders. The number of shares of our common stock reserved for issuance under the 2011 Plan will be increased (i) from time to time by the number of shares of our common stock forfeited upon the expiration, cancellation, forfeiture, cash settlement or other termination of awards under the 2009 Plan, and (ii) at the discretion of our board of directors, on the date of each annual meeting of our stockholders, by up to the lesser of (x) a number of additional shares of our common stock representing 4% of our then-outstanding shares of common stock on such date and (y) 2,758,621 shares of our common stock. During the fiscal year ended December 31, 2016, we granted options to purchase our common stock to certain of our named executive officers and RSUs to certain of our named executive officers pursuant to the 2011 Plan. For a discussion of such option grants and RSUs, please see Compensation Discussion and Analysis Key 2016 Compensation Decisions above, as well as the footnotes accompanying the Grant of Plan Based Awards Table above.

Outstanding Equity Awards at Fiscal Year End

The following table sets forth summary information regarding the outstanding equity awards held by our named executive officers at December 31, 2016.

Name	Grant Date	Number of Securities Underlying Unexercised Options (#)	Number of Securities Underlying Unexercised Options (#)	Option Exercise Price (\$)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested (\$)
Patrick J. Mahaffy	3/1/2012	150,000		24.74	3/1/2022		
	3/1/2013	187,500	12,500 ⁽¹⁾	21.81	3/1/2023		
	1/10/2014	145,833	54,167 ⁽¹⁾	73.98	1/10/2024		
	3/2/2015	46,875	28,125 ⁽¹⁾	79.05	3/2/2025		
TOTAL		530,208	94,792⁽¹⁾				
Daniel W. Muehl	7/6/2015	12,395	22,605 ⁽¹⁾	84.83	7/6/2025		
	3/1/2016		7,500 ⁽¹⁾	19.37	3/1/2026		
	3/1/2016		5,000 ⁽²⁾	19.37	3/1/2026		
	3/1/2016					2,500 ⁽⁴⁾	111,050
	8/25/2016					8,750 ⁽³⁾	388,675
	8/25/2016		17,500 ⁽¹⁾	22.73	8/25/2026		
	9/1/2016		20,000 ⁽¹⁾	23.59	9/1/2026		
TOTAL		12,395	72,605			11,250	499,725
Gillian C. Ivers Read	3/8/2011	68,965		3.28	3/8/2021		
	3/1/2012	50,000		24.74	3/1/2022		
	3/1/2013	70,312	4,688 ⁽¹⁾	21.81	3/1/2023		
	1/10/2014	51,041	18,959 ⁽¹⁾	73.98	1/10/2024		
	3/2/2015	16,406	9,844 ⁽¹⁾	79.05	3/2/2025		

Edgar Filing: Clovis Oncology, Inc. - Form DEF 14A

	12/19/2016					30,000 ⁽³⁾	1,332,600
TOTAL		256,724	33,491			30,000	1,332,600
Lindsey Rolfe	4/7/2010	23,034		3.08	4/7/2020		
	3/1/2011	17,241		3.28	3/1/2021		
	3/1/2012	30,000		24.74	3/1/2022		
	3/1/2013	37,500	2,500 ⁽¹⁾	21.81	3/1/2023		
	1/10/2014	12,760	4,740 ⁽¹⁾	73.98	1/10/2024		
	2/27/2014	24,791	10,209 ⁽¹⁾	78.38	2/27/2024		
	3/2/2015	5,468	7,032 ⁽¹⁾	79.05	3/2/2025		
	8/3/2015	11,666	23,334 ⁽¹⁾	85.65	8/3/2025		
	12/19/2016					55,000 ⁽³⁾	2,443,100
TOTAL		162,460	47,815			55,000	2,443,100

- 40 -

Table of Contents

Name	Grant Date	Number of Securities Underlying Unexercised Options		Option Exercise Price (\$)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested (\$)
		Exercisable (#)	Unexercisable (#)				
C. Dale Hooks	8/25/2014	29,166	20,834 ⁽¹⁾	46.68	8/25/2024		
	3/2/2015	2,450	3,150 ⁽¹⁾	79.05	3/2/2025		
	2/1/2016		10,000 ⁽²⁾	20.90	2/1/2026		
	2/1/2016		10,000 ⁽¹⁾	20.90	2/1/2026		
	3/1/2016		10,000 ⁽¹⁾	19.37	3/1/2026		
	8/25/2016		27,800 ⁽¹⁾	22.73	8/25/2026		
	8/25/2016					13,900 ⁽³⁾	617,438
TOTAL		31,616	81,784			13,900	617,438
Erle T. Mast	3/8/2011	28,478		3.28	3/8/2021 ⁽⁵⁾		
	3/1/2012	40,000		24.74	3/1/2022 ⁽⁵⁾		
	3/1/2013	45,000		21.81	3/1/2023 ⁽⁵⁾		
TOTAL		113,478					

- (1) These options vest over four years, with 25% of such options vesting on the one-year anniversary of the date of grant, and the remainder vesting in substantially equal installments over the 36 months immediately following such anniversary, subject to continued employment through such date. In the event that a named executive officer's employment is terminated by us without misconduct (as defined in the 2011 Plan) or, other than with respect to Mr. Muehl, due to a resignation for good reason (as defined in the named executive officer's employment agreement), in each case, within twelve months following a change in control, 100% of all outstanding options held by such executive will immediately vest upon such termination.
- (2) These options vest over two years, with 50% of such options vesting on the one-year anniversary of the date of grant, and the remaining 50% vesting on the second anniversary of the date of grant, subject to continued employment through such date. In the event that a named executive officer's employment is terminated by us without misconduct, 100% of all outstanding options held by such executive will immediately vest upon such termination. Mr. Hooks will also be entitled to such accelerated vesting if his employment is terminated due to a resignation for good reason within twelve months following a change in control.
- (3) These restricted stock units vest over four years, with 25% of such restricted stock units vesting on the one-year anniversary of the date of grant, and the remainder vesting in substantially equal installments over the 12 quarters immediately following such anniversary, subject to continued employment through such date. In the event that a named executive officer's employment is terminated by us without misconduct or, other than with respect to Mr. Muehl, due to a resignation for good reason, in each case, within twelve months following a change in control, 100% of all outstanding restricted stock units held by such executive will immediately vest upon such termination.
- (4) These restricted stock units vest over two years, with 50% of the restricted stock units vesting on the one-year anniversary of the date of grant, and the remaining 50% vesting on the second anniversary of the date of grant, subject to continued employment through such date. In the event that a named executive officer's employment is terminated by us without misconduct, 100% of all outstanding restricted stock units held by such executive will immediately vest upon such termination. Mr. Hooks will also be entitled to such accelerated vesting if his

employment is terminated due to a resignation for good reason within twelve months following a change in control.

- (5) We extended the period following Mr. Mast's retirement during which Mr. Mast could exercise his vested non-qualified stock options through March 31, 2017, the 12 month anniversary of his retirement, accordingly, each of Mr. Mast's then unexercised and outstanding stock options expired on March 31, 2017. For additional information, please see Compensation Discussion and Analysis Overview of 2016 Compensation Decisions and Actions above.

Table of Contents**Option Exercises and Stock Vested**

The following table shows certain information regarding stock vested during 2016 with respect to our named executive officers.

Name	Option Awards	Stock Awards
	Number of Shares Acquired on Exercise (#)	Value Realized on Exercise (\$) / Number of Shares Vested (#) / Value Realized on Vesting (\$)
Patrick J. Mahaffy		
Daniel W. Muehl		
Gillian C. Ivers-Read		
Lindsey Rolfe		
C. Dale Hooks		
Erle T. Mast	61,737	904,639

Potential Payments Upon a Termination or Change in Control

Pursuant to their employment agreements, upon certain terminations of employment, Messrs. Mahaffy, Muehl, and Hooks, Ms. Ivers-Read and Dr. Rolfe are entitled to payments of compensation and benefits as described above under Narrative Disclosure to Summary Compensation Table and Grant of Plan Based Awards Table Employment Agreements. The table below reflects the amount of compensation and benefits payable to each named executive officer in the event of (i) an involuntary termination without just cause or a resignation for good reason and (ii) an involuntary termination without just cause or a resignation for good reason within twelve months following a change in control. The amounts shown assume that the applicable triggering event occurred on December 31, 2016, and therefore are estimates of the amounts that would be paid to the named executive officers upon the occurrence of such triggering event. Mr. Mast was no longer employed with us as of December 31, 2016, and therefore was not entitled to any such compensation or benefits.

Name	Type of Payment	Triggering Event	
		Involuntary Termination (\$)	Involuntary Termination within Twelve Months following a Change in Control (\$)
Patrick J. Mahaffy	Cash severance	424,875 ⁽¹⁾	1,501,225 ⁽³⁾
	Benefit continuation	4,048 ⁽²⁾	10,795 ⁽⁴⁾
	Equity acceleration ⁽⁵⁾		282,625
	Gross-up ⁽⁶⁾		
	TOTAL ⁽⁷⁾	428,923	1,794,645
Daniel W. Muehl	Cash severance ⁽⁸⁾	50,000	50,000
	Benefit continuation		
	Equity acceleration ⁽⁵⁾⁽⁹⁾	236,300	1,609,025
	Gross-up ⁽⁶⁾		
	TOTAL	286,300	1,659,025

Edgar Filing: Clovis Oncology, Inc. - Form DEF 14A

Gillian C. Ivers-Read	Cash severance	212,180 ⁽¹⁾	615,322 ⁽³⁾
	Benefit continuation	1,839 ⁽²⁾	3,678 ⁽⁴⁾
	Equity acceleration ⁽⁵⁾		1,438,596
	Gross-up ⁽⁶⁾		893,722
	TOTAL	214,019	2,951,318
Lindsey Rolfe	Cash severance	217,500 ⁽¹⁾	630,750 ⁽³⁾
	Benefit continuation	1,082 ⁽²⁾	2,166 ⁽⁴⁾
	Equity acceleration ⁽⁵⁾		2,499,625
	Gross-up ⁽⁶⁾		1,506,691
	TOTAL	218,582	4,639,232

- 42 -

Table of Contents

Name	Type of Payment	Triggering Event	
		Involuntary Termination (\$)	Involuntary Termination within Twelve Months following a Change in Control (\$)
C. Dale Hooks	Cash Severance ⁽⁸⁾	280,000 ⁽¹⁾	604,000 ⁽³⁾
	Benefit Continuation	2,699 ⁽²⁾	5,398 ⁽⁴⁾
	Equity acceleration ⁽⁵⁾⁽⁹⁾	235,200	1,941,320
	Gross-up ⁽⁶⁾		1,246,225
	TOTAL	517,899	3,796,943

- (1) Includes the value of base salary continuation for nine months, in the case of Mr. Mahaffy, and six months, in the case of our other named executive officers.
- (2) Includes the value of payment of an applicable percentage of the executive's COBRA premiums for nine months, in the case of Mr. Mahaffy, and six months, in the case of our other named executive officers.
- (3) Includes the value of (i) base salary continuation for 24 months, in the case of Mr. Mahaffy, and 12 months, in the case of our other named executive officers and (ii) an amount equal to the named executive officer's target bonus.
- (4) Includes the value of payment of an applicable percentage of the executive's COBRA premiums for 24 months, in the case of Mr. Mahaffy, and 12 months, in the case of our other named executive officers.
- (5) Includes the value of accelerated vesting of all outstanding equity awards, which the executives are entitled to upon an involuntary termination without misconduct or, other than with respect to Mr. Muehl, a resignation for good reason, in each case, within twelve months following a change in control.
- (6) Includes the value of a gross-up payment for payments that result in an excise tax imposed by Section 4999 of the Internal Revenue Code (subject to a maximum gross-up payment of \$2,000,000). The gross-up payments were calculated assuming a 45% tax rate and taking into account the full value of accelerated vesting of all outstanding equity awards and may be higher than the gross-up payments the named executive officers actually would have received.
- (7) Amounts reported with respect to Mr. Mahaffy are based on his 2015 salary since he did not receive a salary increase in 2016, and although he voluntarily waived his base salary in 2016 until the achievement of certain milestones by the Company, his waiver specifically provided that his termination or change in control entitlements would be based on his salary prior to the waiver.
- (8) Cash severance for Messrs. Muehl and Hooks include one-time cash retention bonus equal to \$50,000 and \$100,000, respectively, payable on the first regularly scheduled payroll date in March 2017 and February 2017, respectively, in each case, subject to the employee's continued employment through such date. Per the respective retention bonus agreement, amounts were immediately payable in the case of an involuntary termination or an involuntary termination within twelve months following a change in control.
- (9) In March 2016 Mr. Muehl received 5,000 stock options and 2,500 RSUs, to vest in two equal installments on March 1, 2017 and March 1, 2018, and in February 2016 Mr. Hooks received 10,000 stock options, to vest in two equal installments on February 1, 2017 and February 1, 2018. In the event Mr. Muehl's or Mr. Hooks's employment is terminated by us without misconduct, the vesting of their respective options and RSUs is accelerated in full. Mr. Hooks will also be entitled to such accelerated vesting if his employment is terminated due to a resignation for good reason within twelve months following a change in control.

Table of Contents**Director Compensation*****Director Compensation Table***

The following table summarizes the compensation received by our non-employee directors for the year ended December 31, 2016.

Name	Fees earned or paid in cash (\$)	Option awards (\$)⁽¹⁾⁽²⁾	Total (\$)
Brian G. Atwood	55,000	111,238	166,238
M. James Barrett	82,500	111,238	193,738
James C. Blair	60,000	111,238	171,238
Keith Flaherty	45,000	111,238	156,238
Ginger Graham	47,500	111,238	158,738
Paul H. Klingenstein	50,000	111,238	161,238
Edward J. McKinley	60,000	111,238	171,238
Thorlef Spickschen	47,482	111,238	158,720

- (1) On June 9, 2016, all directors received a grant of options to purchase 10,000 shares of our common stock. As of December 31, 2016, Mr. Blair had 69,655 options outstanding, Dr. Flaherty and Ms. Graham each had 60,001 options outstanding, Mr. McKinley had 44,828 options outstanding and each of the other directors had 102,413 options outstanding.
- (2) Amount represents the fair value of the awards on the date of grant computed in accordance with FASB ASC Topic 718. For a discussion of the assumptions made in the valuation, see Note 9 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2016.

Narrative Disclosure relating to Director Compensation Table***Director Compensation***

During 2016, each of our non-employee directors were entitled to receive a \$40,000 annual cash retainer for their service on our board. In addition, during 2016, the chairman of our board and the chairman of each of our audit, compensation, and nominating and corporate governance committees were entitled to receive an additional annual cash retainer of \$25,000, \$20,000, \$15,000 and \$10,000, respectively. In addition, other members of our audit, compensation and nominating and corporate governance committees were entitled to receive an additional annual cash retainer of \$10,000, \$7,500 and \$5,000, respectively. In addition, each new non-employee director is entitled to a one-time initial stock option grant of stock options to purchase 20,000 shares of common stock and each non-employee director is entitled to an annual grant of stock options to purchase 10,000 shares of common stock. Accordingly, on June 9, 2016, we made grants of options to purchase 10,000 shares of our stock to each of Drs. Barrett, Blair and Spickschen, Messrs. Atwood, Flaherty, Klingenstein and McKinley and Ms. Graham pursuant to the 2011 Plan, at an exercise price per share of \$15.23. The shares subject to the option will vest in equal monthly installments upon completion of each month over a 12 month period.

On April 13, 2017, our compensation committee increased the baseline annual cash retainer paid to each of our non-employee directors for their service on our board to \$50,000, and the additional annual cash retainer paid to the chairman of our board to \$30,000. All other 2017 director compensation will remain at 2016 levels. The 2017 retainer

increases were pro-rated for the first and second quarters of 2017 based on the approval date of April 13, 2017. In order to provide our non-employee directors compensation that is competitive with our publicly-traded peer companies, and to ensure that our compensation practices are generally in line with those of our publicly-traded peer companies, our compensation committee will continue to periodically review our director compensation program.

In addition, as part of its ongoing review of director pay practices, on April 13, 2017, our board of directors adopted stock ownership guidelines for our non-employee directors which require all non-employee directors hold a minimum number of shares of our stock while serving as a director. The guidelines are intended to align

Table of Contents

the interests of non-employee directors with those of our stockholders by requiring non-employee directors to be subject to the same long-term stock price volatility our stockholders experience. The minimum threshold is equal to three times the directors' baseline annual retainer fee, or \$150,000.

When determining whether the directors have met the minimum threshold requirements under the policy, calculations include all shares held outright by the directors and any vested equity awards. Each director initially has five years in order to meet his or her minimum ownership threshold (and one year after a retainer increase). During this five-year phase-in period, the director is not allowed to sell more than 50% of any vested equity awards until he or she has met the applicable minimum threshold. The policy is administered and monitored by our Principal Financial Officer under the direction of the compensation committee. Currently, each of our non-employee directors is in compliance with our stock ownership guidelines.

Table of Contents**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following table and accompanying footnotes set forth certain information regarding the beneficial ownership of our common stock as of April 10, 2017 by:

each person or group of affiliated persons who are known by us to own beneficially more than 5% of our common stock;

each of our named executive officers;

each member of our board of directors and each nominee;

all members of our board of directors and our named executive officers as a group.

The amounts and percentages of shares beneficially owned are reported on the basis of SEC regulations governing the determination of beneficial ownership of securities. Under SEC rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power or investment power over the security, which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 60 days. Securities that can be so acquired are deemed to be outstanding for purposes of computing such person's ownership percentage, but not for purposes of computing any other person's percentage. Under these rules, more than one person may be deemed to be a beneficial owner of the same securities and a person may be deemed to be a beneficial owner of securities as to which such person has no economic interest. Applicable percentages are based on 44,771,319 shares of common stock outstanding on April 10, 2017.

Except as indicated in the footnotes below and subject to applicable community property laws, each of the beneficial owners named in the table below has, to our knowledge, sole voting and investment power with respect to all shares of common stock listed as beneficially owned by them. Unless otherwise indicated, the address for each of the stockholders in the table below is c/o Clovis Oncology, Inc., 5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301.

Name Of Beneficial Owner	Beneficial Ownership	
	Number of Shares	Percent of Total
<i>Stockholders beneficially owning 5% or more of our common stock</i>		
Beneficial owners affiliated with Palo Alto Investors, LLC	3,804,088 ⁽¹⁾	8.5%
Beneficial owners affiliated with PointState Capital LP	3,171,978 ⁽²⁾	7.1%
Consonance Capital Management LP	2,730,887 ⁽³⁾	6.1%
The Vanguard Group	2,622,226 ⁽⁴⁾	5.9%
BlackRock, Inc.	2,607,221 ⁽⁵⁾	5.8%
Beneficial owners affiliated with Partner Fund Management, L.P.	2,562,670 ⁽⁶⁾	5.7%
Beneficial owners affiliated with Integrated Core Strategies (US) LLC	2,268,090 ⁽⁷⁾	5.1%

<i>Officers and Directors</i>		
Patrick J. Mahaffy	1,490,578 ⁽⁸⁾	3.3%
Daniel Muehl	21,613 ⁽⁹⁾	*
Gillian C. Ivers-Read	480,474 ⁽¹⁰⁾	1.1%
Lindsey Rolfe	176,367 ⁽¹¹⁾	*
C. Dale Hooks	48,983 ⁽¹²⁾	*
Brian G. Atwood	530,196 ⁽¹³⁾	1.2%
M. James Barrett	104,135 ⁽¹⁴⁾	*
James C. Blair	1,612,115 ⁽¹⁵⁾	3.6%
Keith Flaherty	60,001 ⁽¹⁶⁾	*
Ginger Graham	60,001 ⁽¹⁷⁾	*

- 46 -

Table of Contents

Name Of Beneficial Owner	Beneficial Ownership	
	Number of Shares	Percent of Total
Paul H. Klingenstein	787,711 ⁽¹⁸⁾	1.8%
Edward J. McKinley	312,844 ⁽¹⁹⁾	*
Thorlef Spickschen	132,531 ⁽²⁰⁾	*
All directors and named executive officers as a group (13 persons)	5,817,549	12.5%

* Represents beneficial ownership of less than 1% of our common stock.

- (1) Based on the information provided in a Schedule 13G, as amended, filed with the SEC on January 12, 2017 by Patrick Lee, MD, Anthony Joonkyoo Yun, MD, Palo Alto Investors, LLC and Palo Alto Healthcare Master Fund II, L.P. According to the Schedule 13G, as amended, (i) Patrick Lee, MD, Anthony Joonkyoo Yun, MD and Palo Alto Investors, LLC share voting and dispositive power over 3,804,088 shares, and (ii) Palo Alto Healthcare Master Fund II, L.P. shares voting and dispositive power over 2,172,359 shares. The principal business address of each of Patrick Lee, MD, Anthony Joonkyoo Yun, MD, Palo Alto Investors, LLC and Palo Alto Healthcare Master Fund II, L.P. is 470 University Avenue, Palo Alto, CA 94301.
- (2) Based on the information provided in a Schedule 13G, as amended, filed with the SEC on February 14, 2017 by SteelMill Master Fund LP, PointState Capital LP and Zachary J. Schreiber. According to the Schedule 13G, as amended, (i) SteelMill Master Fund LP shares voting and dispositive power over 2,149,845 shares, and (ii) PointState Capital LP and Zachary J. Schreiber share voting and dispositive power over 3,171,978 shares. The principal business address of each of SteelMill Master Fund LP, PointState Capital LP and Zachary J. Schreiber is c/o PointState Capital LP, 40 West 57th Street, 25th Floor, New York, NY 10019.
- (3) Based on the information provided in a Schedule 13G, filed with the SEC on February 13, 2017 by Consonance Capital Management LP, Consonance Capital Opportunity Fund Management LP, Mitchell Blutt and Consonance Capman GP LLC. According to the Schedule 13G, (i) Consonance Capital Management LP shares voting and dispositive power over 2,635,487 shares, and (ii) Mitchell Blutt and Consonance Capman GP LLC share voting and dispositive power over 2,730,887 shares. The address of the principal business office of each of Consonance Capital Management LP, Consonance Capital Opportunity Fund Management LP, Mitchell Blutt and Consonance Capman GP LLC is 1370 Avenue of the Americas, Suite 3301, New York, NY 10019.
- (4) Based on the information provided in a Schedule 13G, as amended, filed with the SEC on February 10, 2017 by The Vanguard Group. According to the Schedule 13G, as amended, The Vanguard Group has sole dispositive power over 2,554,667 shares, shared dispositive power over 67,559 shares, sole voting power over 65,067 shares and shared voting power over 4,046 shares. The principal business address of The Vanguard Group is 100 Vanguard Boulevard, Malvern, PA 19355.
- (5) Based on the information provided in a Schedule 13G, as amended, filed with the SEC on January 23, 2017 by BlackRock, Inc. According to the Schedule 13G, as amended, BlackRock, Inc. has sole dispositive power over 2,607,221 shares and sole voting power over 2,544,475 shares. The address of BlackRock, Inc. is 55 East 52nd Street, New York, NY 10055.
- (6) Based on the information provided in a Schedule 13G, as amended, filed with the SEC on February 14, 2017 by Partner Fund Management, L.P., Partner Fund Management GP, LLC, Partner Investment Management, L.P., Partner Investment Management GP, LLC, Brian D. Grossman and Christopher M. James. According to the Schedule 13G, as amended, (i) Partner Fund Management, L.P. and Partner Fund Management GP, LLC share voting and dispositive power over 2,516,956 shares including 1,258,206 shares issuable upon the exercise of convertible notes, and (ii) Mr. Grossman and Mr. James share voting and dispositive power over 2,562,670 shares including 1,258,206 shares issuable upon the exercise of convertible notes. The address of the principal business office of each of Partner Fund Management, L.P., Partner Fund Management GP, LLC, Brian D. Grossman and Christopher M. James is c/o Partner Fund Management, L.P., 4 Embarcadero Center, Suite 3500, San Francisco,

CA 94111.

- (7) Based on the information provided in a Schedule 13G, filed with the SEC on January 11, 2017 by Integrated Core Strategies (US) LLC, ICS Opportunities, Ltd., Integrated Assets, Ltd., Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC and Israel

- 47 -

Table of Contents

- A. Englander. According to the Schedule 13G, Millennium Management LLC and Mr. Englander share voting and dispositive power over 2,268,090 shares. The address of the principal business office of Integrated Core Strategies (US) LLC, ICS Opportunities, Ltd., Integrated Assets, Ltd., Millennium International Management LP, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC and Israel A. Englander is c/o Millennium Management LLC, 666 Fifth Avenue, New York, NY 10103.
- (8) Includes 569,791 shares of common stock subject to outstanding options which are exercisable within the next 60 days.
- (9) Includes 21,613 shares of common stock subject to outstanding options which are exercisable within the next 60 days.
- (10) Includes 270,891 shares of common stock subject to outstanding options which are exercisable within the next 60 days.
- (11) Includes 176,367 shares of common stock subject to outstanding options which are exercisable within the next 60 days.
- (12) Includes 48,983 shares of common stock subject to outstanding options which are exercisable within the next 60 days.
- (13) Includes 102,413 shares of common stock subject to outstanding options which are exercisable within the next 60 days. Based on information provided to us, includes 404,866 shares of common stock held of record by Versant Venture Capital IV, L.P. and 2,550 shares of common stock owned by Versant Side Fund IV, L.P. Voting and investment power over the shares held of record by Versant Venture Capital IV, L.P., and Versant Side Fund IV, L.P. is held by Versant Ventures IV, LLC, their sole general partner. Mr. Atwood is a managing member of Versant Ventures IV, LLC. Mr. Atwood disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and the options held by him.
- (14) Includes 102,414 shares of common stock subject to outstanding options which are exercisable within the next 60 days. Based on the information provided in a Form 4 filed by Mr. Barrett with the SEC on February 27, 2017, includes and 861 shares of common stock held of record by the Barrett 2006 Family Trust (the Barrett Trust). The shares directly held by the Barrett Trust are indirectly beneficially owned by Dr. Barrett's wife, April Barrett, who holds voting and dispositive power over the shares. Dr. Barrett disclaims beneficial ownership of these securities, except to the extent of his actual pecuniary interest therein.
- (15) Includes 69,656 shares of common stock subject to outstanding options which are exercisable within the next 60 days. Based on information provided in a Schedule 13D, as amended, filed by Domain Partners VII, L.P. (Domain Partners VII), DP VII Associates, L.P. (DP VII Associates) and Domain Associates, L.L.C. (Domain Associates) with the SEC on September 25, 2015, includes 1,286,857 shares of common stock held of record by Domain Partners VII, 35,506 shares of common stock held of record by DP VII Associates, 32,760 shares of common stock held of record by Domain Associates, 89,649 shares of common stock held of record by One Palmer Square Associates VII, LLC (One Palmer Square) and 2,927 shares of common stock held of record by Susan W. and James C. Blair Family Partnership (Family). Voting and investment power over the shares held of record by Domain Partners VII and DP VII Associates is held by One Palmer Square, the general partner of Domain Partners VII and DP VII Associates. Voting and investment power over the shares held of record by Family is held by Dr. Blair. Dr. Blair is a managing member of One Palmer Square Associates VII, L.L.C. and Domain Associates, L.L.C. Dr. Blair disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein.
- (16) Includes 60,001 shares of common stock subject to outstanding options which are exercisable within the next 60 days.
- (17) Includes 60,001 shares of common stock subject to outstanding options which are exercisable within the next 60 days.
- (18) Includes 102,413 shares of common stock subject to outstanding options which are exercisable within the next 60 days. Based on information provided in a Schedule 13D, as amended, filed by Aberdare Ventures IV, L.P.,

Edgar Filing: Clovis Oncology, Inc. - Form DEF 14A

Aberdare Ventures IV, L.P. and Aberdare GP IV, LLC with the SEC on July 16, 2013, includes 639,078 shares of common stock held of record by Aberdare Ventures IV, L.P. and 12,755 shares of common stock held of record by Aberdare Partners IV, L.P. Voting and investment power over the shares

- 48 -

Table of Contents

owned by Aberdare Ventures IV, L.P. and Aberdare Partners IV, L.P. is held by Aberdare GP IV, LLC, their general partner. Mr. Klingenstein is a managing member of Aberdare GP IV, LLC. Mr. Klingenstein disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

- (19) Includes 44,828 shares of common stock subject to outstanding options which are exercisable within the next 60 days. Based on information provided to us, includes 17,500 shares of common stock owned by the Priory Fund, of which Mr. McKinley is a director and shares voting and dispositive power with respect to such shares. Based on information provided in a Form 4 filed by Mr. McKinley with the SEC on May 16, 2014, includes 215,815 shares of common stock owned by McKinley/Lavidge Revocable Trust, of which Mr. McKinley is co-trustee and shares voting and dispositive power with respect to such shares. Mr. McKinley disclaims beneficial ownership of the securities held by the Priory Fund, except to the extent of his pecuniary interest therein.
- (20) Includes 102,413 shares of common stock subject to outstanding options which are exercisable within the next 60 days.

Table of Contents

SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than ten percent of a registered class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file.

To our knowledge, based solely on a review of the copies of such reports furnished to us and written representations that no other reports were required, during the year ended December 31, 2016, all officers, directors and greater than ten percent beneficial owners complied with all applicable Section 16(a) filing requirements.

Table of Contents

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

On January 30, 2017, we entered into a Strata Trial Collaboration Agreement (the *Strata Agreement*) with Strata Oncology, Inc. (*Strata*), in order to identify potentially eligible patients for Clovis ongoing TRITON (Trial of Rucaparib in Prostate Indications) clinical trial program, which includes Phase 2 and Phase 3 clinical trials of rucaparib in metastatic castration-resistant prostate cancer, via the Strata Trial (the *Strata Trial*), a nationwide observational study sponsored by Strata under which no-cost sequencing is provided to advanced cancer patients at Strata Trial sites. Keith Flaherty, a member of our Board of Directors, is also a founder, member of the board of directors and owns approximately 3.8% of the fully-diluted equity of Strata. Accordingly, the Strata Agreement constitutes a related party transaction under Item 404(a) of Regulation S-K and was reviewed and approved by the Audit Committee of our Board of Directors.

Other than the Strata Agreement, since the beginning of fiscal year 2016, we have not engaged in any transactions in which the amount involved exceeded or will exceed \$120,000, and in which any of our executive officers, directors or holders of more than 5% of our voting securities, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest, other than compensation, termination and change of control arrangements, which are described under *Executive and Director Compensation* above. We describe below certain other transactions with our directors, executive officers and stockholders.

Director Compensation

For a discussion of the director compensation arrangements, see *Executive and Director Compensation* *Director Compensation* above.

Executive Compensation and Employment Agreements

Please see *Executive and Director Compensation* *Compensation Discussion and Analysis* above for information on compensation arrangements with our executive officers, including option grants and agreements with executive officers.

Indemnification Agreements

We have entered into indemnification agreements with each of our directors and officers, and we have purchased a policy of directors and officers liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. Further, our amended and restated certificate of incorporation and bylaws limits our directors and officers liability to the fullest extent permitted under Delaware corporate law.

Policies and Procedures Regarding Transactions with Related Persons

We have a written policy that sets forth our policies regarding the identification, review, consideration, approval and oversight of related-person transactions. For purposes of our policy only, a related-person transaction is a past, present or future transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any related person are participants, the amount involved exceeds \$120,000 and a related person has a direct or indirect material interest. Transactions involving compensation for services provided to us as an employee, director, consultant or similar capacity by a related person are not covered by this policy. A related person, as determined since the beginning of our last fiscal year, is any executive officer, director or nominee to become director, a holder of more than 5% of our common stock, including any immediate family members of such persons or any

entity in which such a person has a 10% or greater equity interest. Any related-person transaction may only be consummated if our audit committee has approved or ratified the transaction in accordance with the policy guidelines set forth below.

Table of Contents

The policy imposes an affirmative duty upon each director and executive officer to identify, and we will request that significant stockholders identify, any transaction involving them, their affiliates or immediate family members that may be considered a related party transaction before such person engages in the transaction. Under the policy, where a transaction has been identified as a related-person transaction, management must present information regarding the proposed related-person transaction to our audit committee (or, where review by our audit committee would be inappropriate, to another independent body of our board of directors) for review. The presentation must include a description of, among other things, the material facts, the direct and indirect interests of the related persons, the benefits of the transaction to us and whether any alternative transactions are available.

In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval process.

HOUSEHOLDING OF PROXY MATERIALS

The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices and, if applicable, our annual report and other proxy materials, with respect to two or more stockholders sharing the same address by delivering a single Notice and, if applicable, a single set of our annual report and proxy materials, addressed to those stockholders. This practice, which is commonly referred to as householding, potentially means extra convenience for stockholders and cost savings for companies.

This year, a number of brokers with account holders who are our stockholders will be householding our proxy materials. A single Notice and, if applicable, a single set of our proxy materials, will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be householding communications to your address, householding will continue until you are notified otherwise or until you revoke your consent.

If, at any time, you no longer wish to participate in householding and would prefer to receive a separate Notice and, if applicable, a single set of proxy materials, please notify your broker or contact us. To contact us, direct your written request to: Investor Relations, Clovis Oncology, Inc., 5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301 or contact Investor Relations at 303-625-5000. Stockholders who currently receive multiple copies of the Notice or our annual report and other proxy materials at their addresses and would like to request householding of their communications should contact their brokers or us, as applicable.

AVAILABLE INFORMATION

We will provide to any stockholder entitled to vote at our Annual Meeting, at no charge, a copy of our Annual Report on Form 10-K for fiscal 2016 filed with the SEC on February 23, 2017, including the financial statements and the financial statement schedules contained in the Form 10-K. We make our Annual Report on Form 10-K, as well as our other SEC filings, available free of charge through the investor relations section of our website located at <http://ir.clovisoncology.com> as soon as reasonably practicable after they are filed with or furnished to the SEC. Information contained on or accessible through our website or contained on other websites is not deemed to be part of proxy statement. In addition, you may request a copy of the Annual Report on Form 10-K by writing to Clovis Oncology, Inc. Investor Relations at 5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301.

Table of Contents

STOCKHOLDER PROPOSALS TO BE PRESENTED AT NEXT ANNUAL MEETING

Stockholder proposals may be included in our proxy statement for an annual meeting so long as they are provided to us on a timely basis and satisfy the other conditions set forth in SEC regulations under Rule 14a-8 regarding the inclusion of stockholder proposals in company-sponsored proxy materials. For a stockholder proposal to be considered for inclusion in our proxy statement for the annual meeting to be held in 2018, we must receive the proposal at our principal executive offices, addressed to the Secretary, no later than December 27, 2017. In addition, a stockholder proposal that is not intended for inclusion in our proxy statement under Rule 14a-8 may be brought before the 2018 annual meeting so long as we receive information and notice of the proposal in compliance with the requirements set forth in our amended and restated bylaws, addressed to our corporate secretary, Paul E. Gross, at Clovis Oncology, Inc., 5500 Flatiron Parkway, Suite 100, Boulder, Colorado 80301, not later than March 10, 2018 nor earlier than February 8, 2018.

OTHER MATTERS

We do not know of any business other than that described in this proxy statement that will be presented for consideration or action by the stockholders at the Annual Meeting. If, however, any other business is properly brought before the meeting, shares represented by proxies will be voted in accordance with the best judgment of the persons named in the proxies or their substitutes. Please promptly submit your proxy as soon as possible (i) by accessing the Internet site or by calling the toll-free number described in the proxy materials; or (ii) if you receive a paper proxy card by mail, by completing and returning the proxy card mailed to you. All stockholders are urged to complete, sign, date and return the accompanying proxy card in the enclosed envelope to us.

By Order of the Board of Directors

Paul E. Gross
Secretary

Boulder, Colorado

April 26, 2017

Table of Contents

CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY
BOULDER, CO 80301

VOTE BY INTERNET - www.proxyvote.com

Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. EDT on June 7, 2017. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form.

ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS

As a shareholder, you can help reduce the environmental impact of producing hard copy materials by consenting to receiving all future notices of availability of proxy materials or proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access proxy materials electronically in future years.

VOTE BY PHONE - 1-800-690-6903

Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. EDT on June 7, 2017. Have your proxy card in hand when you call and then follow the instructions.

VOTE BY MAIL

Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:

KEEP THIS PORTION FOR YOUR RECORDS
DETACH AND RETURN THIS PORTION ONLY

THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.

For	Withhold	For All	To withhold authority to vote for any individual nominee(s), mark For All Except and write the number(s) of the nominee(s) on the line below.
All	All	Except	

The Board of Directors recommends you vote FOR the following proposal:

1. Election of three Class III directors to hold office until the 2020 Annual Meeting of Stockholders.

Nominees

01 Keith Flaherty, M.D. 02 Ginger L. Graham 03 Edward J. McKinley

The Board of Directors recommends you vote FOR the following: **For Against Abstain**

2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2017.

NOTE: In their discretion, the proxies are authorized to vote on such other business as may properly come before

the Annual Meeting or any adjournment or postponement thereof.

For address change/comments, mark here.

(see reverse for instructions)

Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name, by authorized officer.

Date	Signature (Joint Owners)	Date
------	--------------------------	------

Signature [PLEASE
SIGN WITHIN BOX]

Table of Contents

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:

The Notice and Proxy Statement and Annual Report on Form 10-K are available at www.proxyvote.com

as well as in the Investor Relations section at www.clovisoncology.com

CLOVIS ONCOLOGY, INC.

5500 Flatiron Parkway

Boulder, Colorado 80301

Annual Meeting of Stockholders on June 8, 2017

Proxy Solicited on Behalf of the Board of Directors

The undersigned stockholder(s) of CLOVIS ONCOLOGY, INC. hereby appoint(s) Patrick J. Mahaffy and Paul Gross, and each of them, as attorneys and proxies of the undersigned, with full power of substitution, to attend, vote and act for the undersigned at the Annual Meeting of Stockholders of Clovis Oncology, Inc. to be held on June 8, 2017 at 8:30 a.m., Mountain time, at the St. Julien Hotel, 900 Walnut Street, Boulder, Colorado, 80302, and at any adjournment or postponement of the meeting, upon the matters listed on the reverse side and in accordance with the instructions listed on the reverse side, with discretionary authority as to any and all other business that may properly come before the meeting.

This proxy, when properly executed, will be voted in the manner directed herein by the undersigned stockholder. If no direction is given, this proxy will be voted FOR the nominees for director listed in Proposal 1 and FOR Proposal 2.

Address change/comments:

(If you noted any Address Changes and/or Comments above, please mark corresponding box on the reverse side.)

Continued and to be signed on reverse side